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ABSTRACT OF THE DISSERTATION 
A Desmosomal Protein Interaction Screen Uncovers a Novel Mechanism Underlying 
Cardiac Rhythm Disorders 
by 
Jason Pellman 
Doctor of Philosophy in Biomedical Sciences 
University of California, San Diego, 2017 
Professor Farah Sheikh, Chair 
Professor Robert Ross, Co-Chair 
 
Arrhythmogenic right ventricular cardiomyopathy (ARVC) is a genetic based 
cardiac disease, which is characterized by ventricular dysfunction, fibrofatty 
accumulation, and ventricular arrhythmias culminating in sudden death. ARVC has been 
termed a disease of the desmosome, a type of cell-cell junction, as human genetic 
studies have identified mutations in components of the desmosome as causal for the 
  
 xix 
disease. Desmosomal protein loss is considered a molecular hallmark of ARVC, 
however, the mechanisms controlling desmosomal protein degradation that may impact 
cardiac disease remain uncharacterized. In this dissertation, I aim to better understand 
the mechanisms linking desmosomal biology to development of disease features of 
ARVC. 
 
In my studies, I have identified a novel link between protein degradation defects 
and cardiac arrhythmias in ARVC through identification of a novel cardiac desmosomal 
protein. I performed a yeast-2-hybrid screen using the N-terminus of the desmosomal 
protein, desmoplakin (DSP) and identified a novel interaction with the autophagy 
associated protein synaptosomal associated protein 29 kDa (SNAP29). To determine 
the role of SNAP29 in the heart, I generated a novel cardiac specific SNAP29 knockout 
(SNAP29-cKO) mouse by crossing a SNAP29-floxed mouse line with the cardiac 
specific XMLC2-Cre mouse line. Characterization of this line revealed spontaneous and 
inducible ventricular arrhythmias and lipid droplet accumulation. These defects were 
associated with specific loss of select desmosomal and gap junction proteins and 
accumulation of autophagosome-like and autolysosome-like structures specifically at the 
cardiomyocyte cell-cell junctions. In vitro studies revealed that autophagy is activated 
and targets DSP in the absence of SNAP29. In a DSP-deficient (DSP-cKO) mouse 
model of ARVC, I observed autophagy defects characteristic of SNAP29 deficiency, 
suggesting that SNAP29-mediated autophagy may underlie ARVC. In a SNAP29-null 
mouse model of the human brain and skin disease CEDNIK, I observed characteristic 
desmosomal, gap junction, autophagy, and electrical defects in neonatal hearts as 
observed in SNAP29-cKO and DSP-cKO mouse hearts, suggesting cardiac 
desmosomal defects may underlie CEDNIK. 
  
 xx 
  
In conclusion, my doctoral studies provide evidence for a novel interaction 
between SNAP29 and DSP and a new mechanism regulating cardiac rhythm wherein 
cardiomyocyte SNAP29 protects desmosomes from targeted protein degradation via 
autophagy to restrict ventricular arrhythmias. 
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 Introduction  Chapter 1
Chapter 1 
Introduction 
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1.1 Genetic-based heart disease 
Heart disease remains the most common cause of death worldwide. It is 
estimated to account for over 17 million deaths per year as of 2015 and is predicted to 
increase to over 23 million by 2030 (WHO Report). A large number of factors can 
contribute to development of cardiac disease, however genetic factors are recognized as 
one of the strongest risk factors (Lusis 2003, Kathiresan and Srivastava 2012). Naturally 
occurring genetic mutations have the unique potential to reveal biological mechanisms 
underlying human cardiac disease. A better understanding of these molecular 
mechanisms could identify potential targets for novel therapies. In addition, genetic 
screening can be used as a tool to identify individuals at highest risk for development of 
heart disease and aid in preventive medicine efforts. Causal gene mutations for cardiac 
disease were originally identified by performing genetic linkage analyses in families with 
large pedigrees. The first gene linked to heart disease was identified in 1990, when 
mutations in the sarcomeric protein, β-myosin heavy chain, were discovered as causal 
for hypertrophic cardiomyopathy (Geisterfer-Lowrance, Kass et al. 1990). Since then, 
nearly 1500 mutations in sarcomeric proteins have been associated with familial 
hypertrophic and dilated cardiomyopathy (McNally, Golbus et al. 2013). Many of these 
sarcomeric genes were shown to impact cardiac contractility, suggesting that drugs 
regulating cardiac contractility may be useful therapeutic targets. These studies 
ultimately informed the development of a novel drug class, cardiac myosin activators, 
which are currently in phase II trials for the potential treatment of chronic heart failure 
and left ventricular systolic dysfunction (Lim 2017). This class of drug is able to directly 
bind cardiac myosin to increase its ATPase activity and increase myosin activation 
speed (Malik, Hartman et al. 2011). Causal disease associated mutations have been 
identified for a vast spectrum of cardiac diseases affecting cardiac vasculature, function, 
      
 
3 
and arrhythmias (Curran, Splawski et al. 1995, Garg, Kathiriya et al. 2003, Garg, Muth et 
al. 2005, Malik, Hartman et al. 2011). Arrhythmogenic right ventricular cardiomyopathy 
(ARVC) is a genetic based cardiac disease, which encompasses a spectrum of disease 
manifestations ranging from arrhythmogenic defects to heart failure features, thus has 
the potential to shed light on mechanisms that can broadly relate to many cardiac 
diseases (Thiene, Corrado et al. 2007, Sen-Chowdhry, Morgan et al. 2010). ARVC has 
also been termed a disease of the desmosome, as human genetic studies have 
identified mutations in components of the desmosomal cell-cell junction as causal for the 
disease (Sen-Chowdhry, Morgan et al. 2010). Thus, the study of ARVC has the potential 
to provide new insights on underlying mechanisms regulating cardiac desmosomal 
biology as well as how defects in desmosomal function can contribute to development of 
broad cardiac disease features. 
 
1.2 Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC) 
1.2.1 Clinical features of ARVC 
ARVC is a genetic-based heart disease that was originally described as a right 
ventricular disease; however, more recent studies have identified patients with left-
dominant and bi-ventricular dysfunction (Thiene, Corrado et al. 2007, Sen-Chowdhry, 
Morgan et al. 2010). In addition to ventricular dysfunction, patients also display fibrofatty 
replacement, and ventricular arrhythmias leading to sudden death (Thiene, Corrado et 
al. 2007, Sen-Chowdhry, Morgan et al. 2010). Ventricular arrhythmias and risk of sudden 
death increases with exercise (Corrado, Basso et al. 2003). There is also evidence of 
heterogeneity in ARVC disease features as patients are described as exhibiting purely 
electrical abnormalities (cardiac arrhythmias alone) and others exhibiting overt structural 
abnormalities (cardiac arrhythmias plus ventricular dysfunction and/or fibrofatty 
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replacement) (Dalal, Nasir et al. 2005, Thiene, Corrado et al. 2007). The early stages of 
electrical disease have been referred to as the clinically “concealed” phase during which 
sudden death may be the first manifestation of the disease (Basso, Thiene et al. 1996, 
Dalal, Nasir et al. 2005). The disease can also sometimes progress from electrical to 
structural disease features (Dalal, Nasir et al. 2005). ARVC is responsible for 10% of 
sudden cardiac deaths in people ≤65 years of age and 24% in people ≤30 years of age 
(Tabib, Miras et al. 1999, Tabib, Loire et al. 2003). The prevalence of ARVC is 1 in 1000-
5000 people depending on the geographical region, though the prevalence may be 
higher as some patients are undiagnosed or misdiagnosed due to poor diagnostic 
markers (Peters, Trummel et al. 2004, Thiene, Corrado et al. 2007). Growing evidence 
also reveals earlier postnatal onset since pediatric populations ranging from infants to 
children in their teens are also particularly vulnerable to ARVC (Daliento, Turrini et al. 
1995, Nishikawa, Ishiyama et al. 1999, Garcia-Gras, Lombardi et al. 2006, Rey, 
Rodriguez-Nunez et al. 2007, Wong, AbdurRazak et al. 2008), highlighting the critical 
need for research to help identify early mechanisms driving ARVC and the need for 
treatment strategies in patients that target the disease at earlier stages. 
 
1.2.2 Genetics of ARVC 
Human genetic studies have linked up to 30-60% ARVC cases to mutations in 
classic genes encoding components of the desmosome, a type of cell-cell junction (Sen-
Chowdhry, Syrris et al. 2007, Bhuiyan, Jongbloed et al. 2009, den Haan, Tan et al. 2009, 
Bao, Wang et al. 2013, Zhou, Chen et al. 2015). Thus, ARVC is termed a cardiac 
disease of the desmosome (Sen-Chowdhry, Morgan et al. 2010).  The cardiac 
desmosome is made up of five major proteins: desmoplakin, (DSP), plakophilin 2 
(PKP2), plakoglobin (JUP), desmocollin 2 (DSC2), and desmoglein 2 (DSG2). ARVC-
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associated mutations have been identified in all desmosomal genes (Bhuiyan, 
Jongbloed et al. 2009, Bao, Wang et al. 2013). Most mutations are thought to be 
autosomal dominant; however, recessive mutations have also been identified (Norgett, 
Hatsell et al. 2000, Rampazzo, Nava et al. 2002, Alcalai, Metzger et al. 2003, Uzumcu, 
Norgett et al. 2006, Al-Owain, Wakil et al. 2011). DSP was the first desmosomal gene 
linked to autosomal dominant ARVC (Rampazzo, Nava et al. 2002). Interestingly, 
mutations in DSP have been associated with left-dominant and biventricular forms of 
ARVC (Norman, Simpson et al. 2005, Corrado and Thiene 2006, Te Riele, Bhonsale et 
al. 2012). In addition, recessive mutations in DSP have been associated with the 
cardiocutaneous disease, Carvajal syndrome, which was first described in a population 
in Ecuador that harbored ARVC as well as skin and hair defects including epidermolytic 
palmoplantar keratoderma, and wooly hair, respectively (Carvajal-Huerta 1998). 
Recessive mutations in JUP have also been associated with the cardiocutaneous 
disease, Naxos disease (Protonotarios, Tsatsopoulou et al. 1986). Naxos disease was 
first described in a population on the Greek island of Naxos (Protonotarios, 
Tsatsopoulou et al. 1986). The syndrome features include ARVC in addition to skin and 
hair defects, which include palmoplantar keratoderma and wooly hair (Protonotarios, 
Tsatsopoulou et al. 1986). More recently, a novel recessive DSC2 mutation was 
identified in patients with ARVC that also harbored palmoplantar keratoderma, and 
woolly hair (Simpson, Mansour et al. 2009). These cardiocutaneous diseases highlight 
the importance of the desmosome not only in the heart but also the skin. 
 Non-desmosomal genes have also been implicated in ARVC through linkage 
analysis of families affected by ARVC or candidate gene sequencing of patient 
populations. The first locus identified through linkage analysis was transforming growth 
factor β 3 (TFGβ3) (Rampazzo, Nava et al. 1994, Beffagna, Occhi et al. 2005). Both 5’ 
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UTR and 3’ UTR mutations in TGFβ3 mutations have been associated with ARVC and 
shown to increase expression of TGFβ3 in vitro (Beffagna, Occhi et al. 2005). TGFβ3 
has established roles as a positive regulator of cardiac fibrosis (Leask and Abraham 
2004), suggesting that these activating mutations may increase the fibrotic disease 
features associated with ARVC. Although the role of TGF-β3 remains to be determined 
in ARVC, TGFβ signaling was increased in hearts of a cardiac-specific JUP knockout 
mouse model, that exhibited features of ARVC including, biventricular dysfunction, 
fibrosis, spontaneous ventricular arrhythmias, and ultrastructural defects (Li, Liu et al. 
2011), suggesting that TGFβ signaling pathways may be impacted by ARVC.  
The cardiac ryanodine receptor (RYR2) was first associated with familial ARVC 
(Rampazzo, Nava et al. 1995, Tiso, Stephan et al. 2001); however, independent studies 
have also associated mutations in RYR2 with catecholaminergic polymorphic ventricular 
tachycardia (CPVT) (Cerrone, Napolitano et al. 2009, Yano, Yamamoto et al. 2009). 
Both ARVC and CPVT exhibit similar cardiac arrhythmia features including exercise 
induced tachycardia suggesting that they may share similar underlying electrical defects 
driving disease (Comelli, Gonzi et al. 2014, Patel, Shah et al. 2015). RYR2 is a 
sarcoplasmic reticulum protein that controls Ca2+ release during cardiomyocyte 
contraction (Marx and Marks 2013). Exogenous expression of ARVC-associated RYR2 
mutant proteins (G1885E and G1886S) in HEK293 cells revealed increased Ca2+ 
leakiness, which may alter calcium dynamics (Koop, Goldmann et al. 2008). It has been 
proposed that an unrecognized role for calcium sensitive signaling may exist in ARVC 
(van Opbergen, Delmar et al. 2017), however, these mechanisms remain to be 
dissected. 
Mutations in the giant sarcomeric protein titin (TTN) have also been associated 
with a biventricular form of ARVC (Rampazzo, Nava et al. 1997, Taylor, Graw et al. 
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2011). However, TTN mutations have been more commonly associated with dilated 
cardiomyopathy (DCM) as well as hypertrophic cardiomyopathy (HCM) (Satoh, 
Takahashi et al. 1999, Itoh-Satoh, Hayashi et al. 2002, Herman, Lam et al. 2012). TTN is 
expressed longitudinally along the sarcomere and connects the Z-disc to the M-band to 
mediate passive and restorative/diastolic forces during contraction (LeWinter and 
Granzier 2010). In vitro studies performed on an ARVC-associated mutation in TTN 
(T2896I) suggested alterations in protein stability as a mechanism underlying the 
mutation as it lead to increased unfolding of the immunoglobulin-like domain 10 (Ig10) 
(Taylor, Graw et al. 2011). In vivo analysis of a different ARVC-associated TTN mutation 
(T2850I) expressed in mice through genetic knock-in revealed left ventricular diastolic 
dysfunction (Bogomolovas, Fleming et al. 2016). Although other key ARVC features 
were not reported, changes in TTN conformational dynamics were observed that may 
suggest potentially distinct disease mechanisms associated with non-native sarcomeric 
interactions and TTN instability leading to reduced I-band compliance (Bogomolovas, 
Fleming et al. 2016). Thus, the precise mechanisms of how the identified TTN mutations 
may lead to classic ARVC disease features remain unclear. 
A locus containing transmembrane protein 43 (TMEM43), which codes for the 
protein LUMA, has also been associated with ARVC in a patient population in New 
Foundland, Canada (Ahmad, Li et al. 1998, Merner, Hodgkinson et al. 2008). TMEM43 
mutations are also associated with Emery Dreifuss muscular dystrophy, which affects 
both skeletal muscle and the heart (Liang, Mitsuhashi et al. 2011). TMEM43 mutations 
have also been detected in patients with DCM, though a causal relationship is unproven 
(Milting, Klauke et al. 2015). TMEM43 is a member of the LINC (linker of nucleoskeleton 
and cytoskeleton) complex that forms the mechanical link between the nucleus and 
cytoskeleton (Meinke, Nguyen et al. 2011). Using patient fibroblasts from TMEM43 
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mutation positive (S358L) ARVC patients, it was observed that mutant nuclei had 
increased stiffness in culture (Milting, Klauke et al. 2015). In vitro studies expressing 
mutant TMEM43 in HL-1 cells showed (i) reduced zonula occludens 1 (ZO-1), an ICD 
protein, (ii) mislocalized JUP and α-catenin, which are also ICD proteins (iv) altered 
Cx43 phosphorylation and (v) reduced conduction velocity, suggesting a potential role 
for TMEM43 in molecular and disease hallmarks for ARVC (Siragam, Cui et al. 2014). 
However, the role of TMEM43 in the heart and ARVC remains to be assessed. 
Desmin (DES) mutations have also been associated with ARVC (Melberg, 
Oldfors et al. 1999, Klauke, Kossmann et al. 2010). However, DES has also been 
associated with many other muscle diseases including DCM (Li, Tapscoft et al. 1999), 
HCM (Olive, Armstrong et al. 2007), restrictive cardiomyopathy (RCM) (Hager, 
Mahrholdt et al. 2006), myofibrillar myopathy (Goldfarb, Park et al. 1998), neurogenic 
scapuloperoneal syndrome (Walter, Reilich et al. 2007), and limb girdle muscular 
dystrophy (Cetin, Balci-Hayta et al. 2013). Interestingly, patients with DES associated 
ARVC mutations have been observed with and without skeletal muscle myopathy 
suggesting that mechanisms may be shared between cardiac and skeletal muscle 
(Melberg, Oldfors et al. 1999, Klauke, Kossmann et al. 2010). DES forms the 
intermediate filament network in cardiomyocytes and mechanically links the 
desmosome, sarcomere, nucleus and costamere (Azzimato, Genneback et al. 2016). 
Hearts from patients harboring DES associated ARVC mutations, exhibited cytoplasmic 
aggregates associated with reduced DSP and PKP2 protein levels, suggesting that 
mechanisms related to desmosomal protein loss may be at play (Klauke, Kossmann et 
al. 2010, Otten, Asimaki et al. 2010).  
Through candidate gene sequencing, the R14del phospholamban (PLN) 
mutation was identified in a large ARVC patient population in the Netherlands (van der 
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Zwaag, van Rijsingen et al. 2012). This same ARVC associated mutation was also 
identified in DCM patients that exhibited prevalent cardiac arrhythmias, suggesting that 
PLN may be involved in shared mechanisms in ARVC and DCM (van der Zwaag, van 
Rijsingen et al. 2012). The recently identified existence of left dominant and biventricular 
ARVC (Michalodimitrakis, Papadomanolakis et al. 2002) suggest that these two 
diseases may be more similar than previously appreciated. PLN has established roles in 
calcium handling, and loss of PLN function in mice has been previously shown to lead to 
DCM (MacLennan and Kranias 2003). Human induced pluripotent stem cell (hiPSC) 
derived cardiomyocytes from patients with the R14del mutation were shown to exhibit 
defects in PLN localization and Ca2+ handling (Karakikes, Stillitano et al. 2015). Changes 
in calcium handling have been linked to pathogenic mechanisms in cardiac disease, 
however it remains unclear how this PLN mutation and calcium handling defects may 
drive classic ARVC disease features. 
Mutations in lamin A (LMNA) have also been identified in patients with ARVC 
(Quarta, Syrris et al. 2012, Kato, Takahashi et al. 2016). However, similar to many of the 
non-desmosomal genes associated with ARVC, it has been associated with multiple 
systemic diseases including Hutchinson-Gilford progeria (De Sandre-Giovannoli, 
Bernard et al. 2003), Emery Dreifuss muscular dystrophy (Bonne, Di Barletta et al. 
1999), and DCM with conduction disease (Fatkin, MacRae et al. 1999, MacLeod, Culley 
et al. 2003). LMNA is a structural protein of the nuclear membrane and contributes to 
stiffness of the nuclear envelope (Carmosino, Torretta et al. 2014). Genetic knockout of 
LMNA in mouse embryonic fibroblasts has demonstrated increased nuclear deformation, 
defective mechanotransduction, and impaired viability under mechanical strain 
(Lammerding, Schulze et al. 2004). Interestingly, altered response to mechanical stress 
has previously been proposed as a disease mechanism underlying ARVC (Protonotarios 
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and Tsatsopoulou 2004, Basso, Corrado et al. 2009); however, the precise mechanisms 
connecting LMNA function to ARVC associated mutations remain to be examined. 
Mutations in the sodium voltage gated channel alpha subunit 5 (SCN5A) have 
recently been identified in patients with ARVC (Erkapic, Neumann et al. 2008). Mutations 
in SCN5A have also been previously associated with long QT syndrome type 3, Brugada 
syndrome, progressive cardiac conduction disease, and DCM (Remme 2013). SCN5A is 
a major channel responsible for Na+ release during cardiomyocyte excitation (Miller, 
Wang et al. 2014). Though it is not known how SCN5A mutations affect the heart in vivo, 
expression of ARCV-associated SCN5A mutations in hiPSC-derived cardiomyocytes 
revealed reduced sodium current (Te Riele, Agullo-Pascual et al. 2017) which has also 
been observed in a heterozygous PKP2 knockout mouse model that exhibits 
arrhythmogenic features found in ARVC (Cerrone, Noorman et al. 2012). Stimulated 
PKP2 deficient neonatal mouse cardiomyocyte cultures displayed arrhythmic behavior 
including vortex shedding, wavebreaks, and rotors that were dependent on sodium 
current kinetics (Deo, Sato et al. 2011). Altogether, these findings suggest that SCN5A 
may have link to the arrhythmic features of ARVC; however, its connection to the 
structural features of ARVC has not been examined. 
Mutations in the fascia adherens junction (FAJ) protein, αT-catenin (CTNNA3) 
were also found in patients with ARVC (van Hengel, Calore et al. 2013). These 
mutations appear to disrupt the interaction between αT-catenin and β-catenin in vitro 
(van Hengel, Calore et al. 2013), though mouse models targeting desmosomal 
mutations/loss and leading to ARVC have otherwise exhibited no FAJ involvement 
(Saffitz, Asimaki et al. 2009, Sheikh, Ross et al. 2009). In addition, cardiac-specific αT-
catenin knockout mice exhibited left ventricular dysfunction without major classic ARVC 
features (Li, Goossens et al. 2012). Thus, ARVC-associated αT-catenin mutations may 
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not function as loss-of-function mutations and the role of αT-catenin in ARVC remains 
unclear.  
Although there remain gaps in knowledge of how the aforementioned non-
desmosomal genes directly lead to ARVC, ultrastructural evaluation of cardiac biopsies 
from ARVC patient hearts with no known mutation and with classic desmosomal 
mutations reveal that desmosomal ultrastructural defects are a common feature 
regardless of the genetic mutation (Basso, Czarnowska et al. 2006). These results 
suggest that mechanisms associated with desmosomal protein loss may be a common 
underlying mechanism impacted by ARVC and warrant further study. 
 
1.3 The Cardiac Desmosome 
1.3.1 The cardiac intercalated disc 
In cardiac muscle, desmosomes are located at cell-cell junctions between 
cardiac muscle cells known as the intercalated disc (ICD) (Sheikh, Ross et al. 2009). 
The ICD houses multiple protein complexes known to couple mechanical and electrical 
activity between neighboring cardiomyocytes including desmosomes, FAJ, and gap 
junctions.  
Mechanical coupling is mediated by desmosomal junctions and FAJ. The cardiac 
desmosome is classically made up of three types of proteins: plakins (desmoplakin; 
DSP), armadillo proteins (plakophilin 2; PKP2 and plakoglobin; JUP), and desmosomal 
cadherins (desmocollin 2; DSC2 and desmoglein 2; DSG2). The desmosome interacts 
with the intermediate filament network, made of desmin in the heart, through the DSP C-
terminal domain. The DSP N-terminus binds to the armadillo proteins and desmosomal 
cadherins through its N-terminus, and is therefore though to be a “hotspot” for 
desmosomal protein interactions (Smith and Fuchs 1998). Intercellular desmosomal 
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interactions are mediated by desmosomal cadherin binding in the intercellular space. In 
addition to the classical desmosomal proteins, new protein interactions have been 
identified at the desmosome. The scaffolding protein myozap and the p53 inhibitor, 
inhibitor of apoptosis-stimulating protein of p53 (iASPP), have separately been observed 
in a complex with DSP (Seeger, Frank et al. 2010). The cytoskeletal adaptor protein 
ankyrin G has also been identified at the ICD through interactions with both PKP2 and 
the gap junction protein connexin 43 (Sato, Coombs et al. 2011). Ion channels have also 
been found to complex with desmosomal proteins. For example, the voltage gated 
sodium channel NaV1.5 associated with PKP2 and DSG2 in cardiomyocytes (Sato, 
Musa et al. 2009, Rizzo, Lodder et al. 2012). The ventricular ATP-sensitive potassium 
channel subunits Kir6.2 and SUR2A have also been found in a complex with PKP2 and 
JUP (Hong, Bao et al. 2012). 
The FAJ also consists of three major classic types of proteins: catenin-related 
proteins (vinculin and α-actinin), catenins (α-, β-catenin, γ-catenin/plakoglobin, and 
p120-catenin), and cadherins (N-cadherin; NCAD) (Montonen, Aho et al. 2001, Sheikh, 
Ross et al. 2009). The FAJ interacts with the actin cytoskeleton through the catenin-
related proteins, which in turn bind to the catenins and the cadherins. Intercellular 
interactions are mediated by binding of cadherins in the intercellular space. 
Coxsackievirus and adenovirus receptor (CAR) has been identified at the ICD through 
interactions with β-catenin and is thought to influence gap junction function through 
interactions with connexin 45 (Lim, Xiong et al. 2008). More recently, Xinα and Xinβ 
have been identified to interact with the FAJ catenin proteins β-catenin and p120-catenin 
as well as with the actin binding protein cortactin (Wang, Lu et al. 2013).  
Electrical coupling is mediated by gap junctions, which are composed of 
connexin proteins arranged in corresponding hexamers, or connexons, on adjacent 
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cardiomyocyte plasma membranes. The predominant connexin in the heart is connexin 
43 (Cx43). However, subpopulations of cardiomyocytes in the cardiac conduction 
system express different connexins. The predominant connexins in the sinus node are 
Cx30, Cx30.2, CX45; those in the atrioventricular node are Cx30.2, Cx45; and those in 
the His-Purkinje network are Cx40, Cx45 (Mezzano, Pellman et al. 2014). Additional 
proteins have also been identified interacting at the gap junction. These include zonula 
occludens-1 (ZO-1), which is thought to interact with Cx43 and has been proposed as a 
positive regulator of gap junction formation (Giepmans and Moolenaar 1998, Toyofuku, 
Yabuki et al. 1998, Rhett, Jourdan et al. 2011).  
The ICD has been revealed as an increasingly complex structure based on 
evidence of new protein interactions that bridge components from different complexes 
together. For example, a direct interaction between the FAJ protein αT-catenin and the 
desmosomal protein PKP2 was recently identified (Goossens, Janssens et al. 2007), 
suggesting that additional uncharacterized interactions between junctional components 
may exist. Recent studies using immunogold electron microscopy have also uncovered 
evidence of structures that encompass a mixture of junctional components 
(desmosomes and FAJs), which are referred to as the area composite (Borrmann, 
Grund et al. 2006, Franke, Borrmann et al. 2006). Furthermore, while the link between 
the desmosome and ARVC is established, the mechanisms that bridge desmosome 
function to the rest of the cardiomyocyte are unknown, suggesting that there may exist 
novel proteins and pathways at the ICD that mediate these processes. Furthermore, 
there are distinct clinical phenotypes associated with alterations in different complexes 
(e.g., NCAD loss is associated with DCM and desmosomal loss is associated with 
ARVC) (Sheikh, Ross et al. 2009). Mouse models have been used as a pivotal tool to 
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assess how complex-specific proteins and mechanisms may function in the ICD and 
heart. 
 
1.3.2 Mouse models of ARVC: Insight into Mechanisms 
Multiple genetic mouse models have been generated to recapitulate ARVC 
disease features (Table 1 and Table 2). The first mouse knockout model targeted DSP 
using the cardiac-specific promoter alpha myosin heavy chain (αMHC)-Cre (Garcia-
Gras, Lombardi et al. 2006). Although homozygous DSP loss resulted in embryonic 
lethality, cardiac-specific heterozygous DSP deficient mice displayed a subset of ARVC 
features including left ventricular dysfunction, fibrofatty replacement, as well as 
spontaneous and pacing-induced arrhythmias. Using siRNA-mediated knockdown of 
DSP in HL-1 (atrial) cells, it was shown that DSP loss leads to JUP translocation to the 
nucleus to suppress Wnt/β-catenin signaling and drive adipogenic and fibrotic signaling 
pathways (Garcia-Gras, Lombardi et al. 2006). The role of Wnt signaling in ARVC was 
further assessed in recent studies that characterized a mouse model expressing a 
dominant negative form of Rho-kinase (DN-RhoK) under the control of the early 
embryonic heart promoter, smooth muscle protein 22 α (SM22α) (Ellawindy, Satoh et al. 
2015). Rho-kinase, a downstream effector of the small GTPase Rho, is an intracellular 
regulator of Wnt signaling (Shimokawa and Takeshita 2005). Hearts from DN-RhoK mice 
exhibit features of ARVC including cardiac dysfunction, fibrofatty accumulation, 
ventricular arrhythmias and ultrastructural defects resulting in premature sudden death 
(Ellawindy, Satoh et al. 2015). Hearts from DN-RhoK mice exhibited a switch in Wnt 
signaling as evidenced by a reduction in Wnt/β-catenin signaling pathways and 
stimulation of pro-adipogenic Wnt5a signaling pathways (Ellawindy, Satoh et al. 2015). 
Furthermore, studies exploiting heterozygous DSP knockout mice driven by Nkx2.5-Cre 
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as well as a JUP transgenic model driven by the αMHC promoter also demonstrated that 
adipogenic genes were activated by Hippo signaling, and these pathways were elevated 
in cardiac biopsies from ARVC patients (Chen, Gurha et al. 2014). Inhibition of the Hippo 
mediators large tumor suppressor kinases 1 and 2 (LATS1 and LATS2) in diseased 
PKP2-deficient HL-1 cells was also able to decrease adipogenesis (Chen, Gurha et al. 
2014); however, the effects of Hippo inhibition in the heart and in ARVC have not been 
determined.  
To more closely determine the cell populations contributing to the fatty deposition 
in ARVC, three DSP knockout lines with an enhanced yellow fluorescent protein (EYFP) 
lineage tracing reporter were generated using the (i) Nkx2.5, an early and pan-cardiac 
promoter, (ii) Mef2C, a second heart field promoter, and (iii) αMHC, a late cardiogenesis 
promoter (Lombardi, Dong et al. 2009). Analysis of these lines revealed EYFP 
expression in a majority of adipocytes in Nkx2.5 and Mef2c lineage traced hearts and 
very few EYFP positive adipocytes in αMHC lineage traced hearts (Lombardi, Dong et 
al. 2009). These findings suggested that adipocytes in ARVC may arise from the 
secondary heart field (Lombardi, Dong et al. 2009). Independent studies from our lab 
that generated a novel genetic mouse model of ARVC by targeting DSP loss using the 
cardiomyocyte specific myosin light chain 2 ventricular isoform (MLC2v)-Cre (Lyon, 
Mezzano et al. 2014) was also used to lineage trace the cellular origin of fatty deposition 
in ARVC by crossing this mouse line to the R26RtdTomato reporter line. In this model, 
TomatoRed positive cells co-localizing with an adipocyte lipid droplet marker (double 
positive for perilipin and TomatoRed (representative of MLC2v)) were observed in the 
subepicardial layer of knockout mice, suggesting that the fatty accumulation is of 
cardiomyocyte origin (Lyon, Mezzano et al. 2014). In a separate study, an adipocyte 
progenitor population was also identified by sorting for c-Kit+:Sca1+ cardiac progenitor 
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cells (CPCs) in a mouse model of ARVC utilizing overexpression of wildtype JUP to 
mimic nuclear accumulation of JUP)under the αMHC promoter (Lombardi, Dong et al. 
2009). This population exhibited enhanced adipogenic signaling, suggesting that 
adipocytes in ARVC may arise in part from CPCs.  Interestingly, studies using biopsies 
from ARVC human hearts suggested that adipocyte progenitors originated from a non-
cardiomyocyte cell population, the cardiac mesenchymal stromal cells (C-MSC) 
(Sommariva, Brambilla et al. 2016). It remains unclear whether this is a difference due to 
model system or if there may be multiple cardiac cell populations that can give rise to 
adipocytes in the heart in ARVC. 
To assess the effects of homozygous recessive loss of DSP, which has been 
associated with a biventricular form of ARVC in patients (Uzumcu, Norgett et al. 2006), 
our lab targeted DSP loss using MLC2v-Cre (Lyon, Mezzano et al. 2014). This mouse 
recapitulated many of the postnatal features of a biventricular form of ARVC including 
fibrofatty replacement of the ventricles, biventricular dysfunction, ventricular arrhythmias 
and premature death. These ventricular arrhythmias could also be exacerbated with 
exercise and catecholamine stimulation (Lyon, Mezzano et al. 2014) similar to what is 
observed in athletes with ARVC where exercise induced catecholamine release is a 
trigger of ventricular arrhythmias and sudden death (Furlanello, Bertoldi et al. 1998, 
Heidbuchel, Hoogsteen et al. 2003). This model also uncovered right bundle branch 
block associated with loss of connexin 40 (Lyon, Mezzano et al. 2014) the former of 
which is a clinical feature observed in ARVC patients (Fontaine, Frank et al. 1984). In 
contrast to the heterozygous αMHC-Cre DSP knockout mouse model (Garcia-Gras, 
Lombardi et al. 2006), this model did not exhibit loss of JUP suggesting that this 
biventricular form of ARVC may target different underlying mechanisms (Lyon, Mezzano 
et al. 2014). In vitro studies exploiting DSP floxed cardiomyocytes demonstrated that 
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loss of DSP triggered primary and early loss of Cx43 and conduction defects in the 
absence of fibrofatty deposition and prior to complete loss of desmosomal proteins 
(Lyon, Mezzano et al. 2014), suggesting that there may exist crosstalk between 
desmosomes and gap junctions. These studies provided validation to independent 
studies in young heterozygous DSP deficient mice using αMHC-Cre and early stage 
ARVC patient tissues that suggested that Cx43 loss may be an early feature of ARVC 
(Gomes, Finlay et al. 2012).  
Cardiac-specific transgenic models have also been generated to more closely 
evaluate the impact of desmosomal mutations in ARVC. Transgenic cardiac-specific 
overexpression of DSP mutations at the N-terminal region (V30M and Q90R) and C-
terminus (R2834H) of DSP were generated (Yang, Bowles et al. 2006). Transgenic 
models overexpressing N-terminus DSP mutations resulted in embryonic lethality after 
E13.5 with cardiac defects (Yang, Bowles et al. 2006). However, transgenic 
overexpression of C-terminal DSP mutation, R2834H, which is thought to disrupt the 
interaction between DSP and desmin, survived postnatally and developed biventricular 
cardiac dysfunction, cardiac fibrosis, lipid accumulation, and ultrastructural defects 
(Yang, Bowles et al. 2006). Although the electrophysiology was not examined, these 
studies demonstrate disruption of desmosomal integrity as a key factor leading to 
structural features associated with ARVC.  
The inhibitor of apoptosis-stimulating protein of p53 (iASSP) was recently 
identified as a novel desmosomal protein able to complex with DSP in the heart and 
implicated in ARVC disease pathogenesis (Notari, Hu et al. 2015). Global iASSP 
knockout mice exhibited biventricular dysfunction, fibrofatty accumulation, and 
ventricular arrhythmias (Notari, Hu et al. 2015). These defects were associated with loss 
of DSP and DES from the ICD (Notari, Hu et al. 2015). Examination of cardiac biopsies 
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from patients with ARVC also revealed loss of iASSP from the ICD (Notari, Hu et al. 
2015), altogether suggesting that loss of iASSP and its interaction with DSP may 
contribute to development of ARVC. 
Several mouse knockout models have also targeted PKP2. The first PKP2 
deficient mouse model was a global PKP2 knockout (Cerrone, Noorman et al. 2012). 
Homozygous PKP2 knockout mice were embryonic lethal at E10.5-E11 (Grossmann, 
Grund et al. 2004); however, examination of heterozygous PKP2 knockout mice 
revealed ultrastructural defects at the ICD with no baseline disease features (Cerrone, 
Noorman et al. 2012). Further analysis of these hearts revealed sodium current 
insufficiency that could be exacerbated with the sodium channel blocker, flecainide, and 
lead to ventricular arrhythmias (Cerrone, Noorman et al. 2012). These arrhythmias 
occurred in the absence of structural disease suggesting that heterozygous loss of PKP2 
levels can impair the function of the voltage-gated sodium channel complex and alter 
cardiac electrophysiology without negatively affecting heart function. To determine the 
impact of ARVC-associated PKP2 mutations, adeno-associated viral (AAV) gene 
delivery methods were used to express mutant PKP2 (R735X) in wildtype mice in vivo 
(Cruz, Sanz-Rosa et al. 2015). No overt phenotype could be observed in these mice at 
baseline; however, right ventricular dysfunction and Cx43 mislocalization could be 
observed after exercise in the absence of cardiac fibrofatty deposition and thus, these 
mice only developed a subset of features associated with ARVC. In addition, the 
electrical features were not determined in this model. Truncations of PKP2 have also 
been previously associated with ARVC (Rasmussen, Nissen et al. 2014). In a recent 
study, transgenic mice were generated that overexpressed a truncated PKP2 (amino 
acids 1-329) at increasing levels of expression (Moncayo-Arlandi, Guasch et al. 2016). 
Hearts from transgenic mice expressing the highest level of truncated PKP2 were shown 
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to exhibit features of ARVC including, ventricular dilation and dysfunction, inducible 
arrhythmias and ultrastructural defects (Moncayo-Arlandi, Guasch et al. 2016). 
Interestingly, the specific truncation in this model was not related to a known ARVC 
mutation; thus, future models expressing truncations related to known ARVC mutations 
may provide further relevance of these findings to humans.  
Mouse models targeting JUP have also been developed. Global homozygous 
loss of JUP leads to embryonic lethality from E10.5-E16.5 (Bierkamp, McLaughlin et al. 
1996, Ruiz, Brinkmann et al. 1996). Global heterozygous loss of JUP does not lead to an 
overt basal phenotype (Kirchhof, Fabritz et al. 2006). However, with age and exercise, 
heterozygous mice exhibit a subset of ARVC features including enlarged right ventricles, 
increased ventricular arrhythmias, and conduction slowing without histological or 
ultrastructural defects (Kirchhof, Fabritz et al. 2006). Interestingly, load reducing therapy 
(furosemide and nitrates) in exercised global heterozygous JUP knockout mice lead to a 
reduction in chamber dilation, arrhythmia inducibility, and Cx43 loss from the ICD, 
suggesting that the increased load on the heart associated with exercise contributes to 
disease progression (Fabritz, Hoogendijk et al. 2011). Cardiac-specific JUP knockout 
mouse have also been generated using the αMHC-Cre (Li, Liu et al. 2011). These mice 
displayed a subset of ARVC disease features including, ventricular dilation, fibrosis, 
arrhythmias, ultrastructural defects, and sudden death without evidence of fatty 
deposition. Interestingly, hearts from these mice exhibited increased TGFβ signaling, 
which along with human clinical studies identifying mutations in TGFβ3 in ARVC patients 
(Beffagna, Occhi et al. 2005) support a potential role for TGFβ3 in ARVC that remains to 
be tested. In contrast to this model, cardiac specific ablation of JUP in adult mice via a 
tamoxifen inducible αMHC-mER-Cre-mER lead to a smaller subset of ARVC disease 
features including ventricular dysfunction, fibrosis, and ultrastructural defects without 
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fatty deposition or arrhythmias (Li, Swope et al. 2011). The presence of cardiac 
arrhythmias in the cardiac specific JUP knockout mouse (Li, Liu et al. 2011) and their 
absence in the inducible cardiac specific JUP knockout mouse (Li, Swope et al. 2011) 
suggest that developmental mechanisms may underlie the distinct disease etiologies.  
The JUP mutation associated with the human disease Naxos (2157del2) has 
also been modeled in mice. The mouse equivalent of the human Naxos disease JUP 
mutation (2157del2) was overexpressed in the heart using the αMHC promoter 
(Lombardi, da Graca Cabreira-Hansen et al. 2011). These mice exhibited left ventricular 
dysfunction, fibrofatty accumulation, and cardiac arrhythmias with underlying nuclear 
localization of mutant JUP (Lombardi, da Graca Cabreira-Hansen et al. 2011). Naxos-
related JUP mutant knock in mice have also been generated to address the role of this 
mutation and its expression in disease (Zhang, Stroud et al. 2015). Genetic knockin of 
the equivalent human Naxos mutation into the endogenous locus of mouse lead to a 
significant downregulation of JUP mRNA associated with perinatal lethality and reduced 
levels of JUP and other desmosomal proteins (Zhang, Stroud et al. 2015). Cardiac 
morphology, fibrosis, and stress markers were not altered in knockin mice and cardiac 
function and electrophysiology were not reported, therefore this model may not exhibit 
features of ARVC at time of death (Zhang, Stroud et al. 2015). In contrast, stabilization 
of Naxos mutant JUP mRNA via fusion of the last 5 exons of the gene lead to restoration 
of mutant JUP protein to wildtype levels and no basal phenotype (Zhang, Stroud et al. 
2015). These findings suggested that restoration of mutant JUP protein levels may have 
potentially therapeutic effects. 
Several mouse models have been used to dissect the mechanisms by which 
JUP, and more specifically accumulation of nuclear JUP, and its downstream signaling 
plays a role in ARVC. Overexpression of wildtype JUP under the αMHC promoter 
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demonstrated that JUP transgenic mouse hearts displayed fibrofatty replacement 
without functional or ultrastructural defects (Lombardi, Dong et al. 2009). Molecular 
analyses revealed the appearance of nuclear JUP and concordant suppression of 
Wnt/β-catenin target genes, suggesting that nuclear JUP translocation may underlie the 
fibrofatty features of ARVC (Lombardi, Dong et al. 2009). A high throughput chemical 
screen identified the glycogen synthase kinase 3 beta (GSK3β) inhibitor, SB216763, as 
an agent capable of preventing heart failure and reducing mortality in an ARVC-like 
zebrafish model overexpressing the Naxos associated JUP mutation (Asimaki, Kapoor et 
al. 2014). Interestingly, GSK3β is itself an inhibitor of Wnt signaling, thus a reduction in 
GSK3β activity is thought to reverse the suppression of Wnt signaling thought to underlie 
ARVC. To test the effect of SB216763 in ARVC, transgenic JUP mutant (2157del2) 
mice, which were shown to exhibit cardiac arrhythmias and fibrosis, were treated with 
SB216763 (Chelko, Asimaki et al. 2016). SB216763 treated JUP mutant mice exhibited 
attenuated arrhythmias and fibrosis (Chelko, Asimaki et al. 2016), suggesting that 
activation of Wnt signaling though inhibition of GSK3β may be an effective therapeutic 
approach in ARVC. 
DSG2 has also been targeted in genetic mouse models. Cardiac specific 
knockout of DSG2 leads to chamber dilation, interstitial and focal replacement fibrosis, 
conduction defects, and ultrastructural defects (Kant, Holthofer et al. 2015). Cardiac 
function and fat deposition were not examined in this model, however calcifying 
cardiomyocyte necrosis was consistently observed in DSG2 knockout hearts (Kant, 
Holthofer et al. 2015). DSG2 mediates direct interactions between each half of the 
desmosome through its extracellular domains (Garrod and Chidgey 2008). The role of 
DSG2 extracellular domains was more directly tested through two mouse models, which 
include DSG2 (EC1 and EC2) knockout mice harboring a DSG2 deletion that lacks the 
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extracellular EC1 and EC2 domains (Krusche, Holthofer et al. 2011, Kant, Krull et al. 
2012) and transgenic mice overexpressing a DSG2 mutation (N271S) between the EC2 
and EC3 domains (Pilichou, Remme et al. 2009). Both models could recapitulate the 
ARVC disease features exhibited by the cardiac-specific DSG2 knockout mice, 
suggesting that the adhesive domains of DSG2 adhesion are critical to desmosomal 
integrity and their loss contributes to disease features of ARVC. In a separate study 
using the same DSG2 mutation (N271S) mouse, electrical and ultrastructural defects 
were observed prior to development of structural features of disease including myocyte 
necrosis and fibrosis suggesting that these may be early features of disease 
(22764152). Similar to PKP2 heterozyogus knockout mice (Cerrone, Noorman et al. 
2012), hearts of these DSG2 transgenic mice also exhibited reduced sodium current 
density (Rizzo, Lodder et al. 2012). These findings suggested that DSG2 loss may also 
contribute to early electrical defects in ARVC through disruption of the NaV1.5 sodium 
channel. Recent studies from an independent group, generated a DSG2 global knockout 
mouse model the exhibited ventricular dysfunction and biventricular fibrosis, though 
electrical or fatty accumulation features were not reported (Chelko, Asimaki et al. 2016). 
Treatment of these mice with the GSK3β inhibitor SB216763 lead to attenuation of 
ventricular dysfunction and fibrosis, suggesting that activation of Wnt signaling though 
inhibition of GSK3β may be an effective therapeutic approach in ARVC. 
Human clinical studies have associated DSC2 mutations with ARVC (Heuser, 
Plovie et al. 2006); however, to date, their role in mice in vivo has not been tested. 
ARVC-associated DSC2 mutants (E102K and I345T) have been overexpressed in HL-1 
cells (Beffagna, De Bortoli et al. 2007). These DSC2 mutations were shown to lead to 
mislocalization of mutant DSC2 to the cytoplasm, suggesting that DSC2 is effectively 
lost from the desmosome in this setting. Independent studies expressing distinct ARVC-
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associated DSC2 mutations (R203C and T275M) in cultured neonatal rat 
cardiomyocytes demonstrated that these mutations prevented proper proteolytic 
cleavage and maturation of DSC2 leading to loss of functional protein (Gehmlich, Syrris 
et al. 2011). These findings altogether suggested that loss of mature DSC2 protein and 
desmosomal protein targeted mechanisms rather than dominant negative activity could 
be responsible for disease development in this setting.  
Altogether these studies suggest that mutations and/or loss of molecular 
components of the classic desmosomal complex, result in loss of desmosomal protein 
levels, which are molecular triggers for ARVC. Despite this link, the mechanisms that 
control desmosomal protein levels (degradation) and function in health and disease 
remain largely undefined.  
 
1.4 Protein Degradation Mechanisms at the ICD 
1.4.1 Protein degradation pathways in the heart 
The heart is a major target of protein quality control as it undergoes constant 
stress and thus, requires constant turnover of cardiac proteins (protein synthesis and 
protein degradation) to maintain cardiac function (Lyon, Lange et al. 2013). Recent 
advances in the field of protein turnover have linked defects in protein degradation to 
human cardiac diseases (Su and Wang 2010). Protein degradation in the heart is 
mediated by two major cellular mechanisms, the ubiquitin-proteasome system (UPS) 
and autophagy (Portbury, Willis et al. 2011). These mechanisms recycle damaged, 
misfolded, or otherwise unneeded proteins into free amino acids to be used again in 
future cellular processes (Portbury, Willis et al. 2011). 
Protein degradation via the UPS begins with selection of a protein target via 
covalent attachment of a ubiquitin moiety in a process known as ubiquitination (Lyon, 
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Lange et al. 2013). This process occurs through a multi-step step enzymatic cascade 
consisting of (i) activation of ubiquitin monomers by the E1 ubiquitin-activating enzyme 
UBA1, (ii) transfer of the activated ubiquitin to an E2 ubiquitin-conjugating enzyme via 
trans-esterification, and (iii) ligation of the ubiquitin to the target protein by an E3-ubquitin 
ligase, ultimately generating a polyubiquitin-tagged protein (Lyon, Lange et al. 2013). 
This newly marked protein can now be recognized by the 26S proteasome for 
degradation (Lyon, Lange et al. 2013). Targeting of proteins for ubiquitination typically 
occurs through binding of a substrate adaptor that links the target protein to the E3-
ubiquitin ligase complex (Lyon, Lange et al. 2013).  
Protein degradation via autophagy begins through sequestration of protein or 
organelle targets into a specialized double membraned vesicle called the 
autophagosome (Portbury, Willis et al. 2011). The steps of autophagy are also 
dependent on an enzymatic cascade that generates the autophagy proteins (ATG) 
conjugate ATG5-ATG12 that converts microtubule associated protein 1 light chain 3 
(LC3-I) to its lipidated form LC3-II, which allows for formation of the autophagosomal 
membrane (Johansen and Lamark 2011). After LC3-II activation the main steps of 
autophagy are (i) cargo sequestration, (ii) fusion with the lysosome, and (iii) degradation. 
Cargo can be non-selectively sequestered or selectively sequestered by cargo-specific 
adaptor proteins including p62 (sequestome-1) and NBR1 (neighbor to Brca1) and ALFY 
(autophagy linked FYVE protein) (Johansen and Lamark 2011). These adaptor proteins 
can also mediate crosstalk between the UPS and autophagy, as p62 and NBR1 can 
recognize polyubiquitinated substrates (Kirkin, McEwan et al. 2009). After degradation, 
the molecular components of the cargo are released and become available for reuse 
(Johansen and Lamark 2011). 
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1.4.2 Protein degradation plays an important role in cardiac disease 
Defects in the UPS have been observed in in cardiac disease including heart 
failure, dilated cardiomyopathy, hypertrophic cardiomyopathy, cardiac hypertrophy, and 
atherosclerosis (Day 2013). In these settings, accumulation of polyubiquitinated proteins 
is the key feature of altered protein degradation (Day 2013). Though accumulation of the 
intermediate product of the UPS, i.e. polyubiquitinated proteins, might suggest reduced 
rates of degradation, further studies have revealed that both increased and decreased 
UPS activity have been observed in diseased settings. In cases of failing and 
hypertrophic cardiomyopathic hearts, reduced proteasomal activity has been observed 
(Predmore, Wang et al. 2010) whereas in cases of dilated cardiomyopathy, increased 
proteasomal activity has been observed (Birks, Latif et al. 2008).  
Mouse models have been used to assess the role of UPS in cardiac disease. 
Upregulation of UPS activity through overexpression of a proteasome subunit has been 
used to determine the relationship between UPS degradation and cardiac injury (Li, 
Horak et al. 2011). In a mouse model of ischemia reperfusion injury, cardiac 
overexpression of the proteasome subunit, PA28α, leads to increased proteasome 
activity and improved recovery after injury (Li, Horak et al. 2011). Conversely, when 
ischemia reperfusion injury was performed in a transgenic mouse model overexpressing 
a catalytically inactive β5 proteasome subunit (β5T1A), mice exhibited a worse response 
to injury (Tian, Zheng et al. 2012). The role of cardiac proteasome activity was also 
assessed in a pressure overload model using abdominal aortic banding (Chen, Ma et al. 
2010). Banded mice treated with the proteasomal inhibitor MG132, exhibited reduced 
cardiac hypertrophy and improved cardiac function compared to untreated mice, 
suggesting that inhibiting proteasome function in a pressure overload setting is beneficial 
(Chen, Ma et al. 2010). Similarly, in a study treating an OVE26 diabetic cardiomyopathy 
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mouse model with MG132 demonstrated that treated mice exhibited attenuated 
cardiomyopathy features (Wang, Sun et al. 2013). Altogether these studies suggest that 
alterations in protein degradation activity via the UPS can be beneficial though this effect 
appears to be highly dependent on disease etiology. 
Autophagy is upregulated in various human heart disease settings (Nishida, Kyoi 
et al. 2009). The lysosomal protein, lysosome-associated membrane glycoprotein 2 
(LAMP2), is disrupted by loss of function mutations in Danon’s disease, where patients 
exhibit hypertrophic cardiomyopathy, skeletal myopathy and muscle wasting (Danon, Oh 
et al. 1981, Cheng and Fang 2012). A key molecular feature of Danon’s disease is the 
accumulation of autophagosomes in cardiomyocytes due to impaired lysosomal 
degradation (Nishino, Fu et al. 2000, Tanaka, Guhde et al. 2000). Autophagosomes 
have also been observed in human dilated cardiomyopathy (Shimomura, Terasaki et al. 
2001) and ischemic heart disease (Elsasser, Vogt et al. 2004, Yan, Vatner et al. 2005), 
though the disease driving mechanisms for the accumulation of autophagosomes remain 
unclear. 
The role of autophagy in cardiac disease has been more directly investigated 
through mouse models. Inducible cardiac specific loss of the autophagy protein Atg5 in 
adult mice, leads to rapid left ventricular dilation and contractile dysfunction (Nakai, 
Yamaguchi et al. 2007). However, constitutive cardiac specific loss of Atg5 leads to a 
much later onset of cardiac disease with sudden death and left ventricular dysfunction, 
suggesting that Atg5 function may be more important for short-term stress responses 
(Nakai, Yamaguchi et al. 2007). Developmental compensation has also been proposed 
to account for these differential responses via a molecular switch from one 
autophagosome production pathway, Unc-51-like kinase dependent, to an alternative 
one, Rab9-dependent (Nishida, Arakawa et al. 2009, Honda, Arakawa et al. 2014). To 
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investigate the role of autophagy in cardiac hypertrophy regression, Atg5 cardiac specific 
knockout mice and wildtype controls were subjected to cardiac hypertrophy induction via 
angiotensin II infusion (Oyabu, Yamaguchi et al. 2013). Wildtype mice exhibited elevated 
autophagic markers upon removal of angiotensin II (Oyabu, Yamaguchi et al. 2013). 
Regression from cardiac hypertrophy was delayed in mice lacking Atg5 compared to 
wildtype controls (Oyabu, Yamaguchi et al. 2013), suggesting that autophagy is 
necessary for regression after unloading of the heart. It has also been shown that the 
FoxO family of proteins are important regulators of autophagy during this process (Cao, 
Jiang et al. 2013, Hariharan, Ikeda et al. 2013). 
Studies in mouse models of cardiac disease have explored the potential for 
therapeutically targeting autophagy. In a mouse model of a desmin-related 
cardiomyopathy generated through transgenic overexpression of mutant chaperone 
protein, αB-crystallin (R120G), autophagy was blunted via heterozygous deletion of 
Beclin-1, a positive regulator of autophagy (Tannous, Zhu et al. 2008). This lead to 
accelerated disease progression (Tannous, Zhu et al. 2008). In a separate study using 
the same αB-crystallin (R120G) mouse, autophagy was upregulated via overexpression 
of Atg7, which lead to an attenuation of disease progression, suggesting that 
upregulation of autophagy can reverse the course of disease in this setting (Bhuiyan, 
Pattison et al. 2013). However, results from mouse models are conflicting in the setting 
of pressure overload. The response to pressure overload (via TAC) was worsened in 
cardiac specific Atg5 knockout mice (Nakai, Yamaguchi et al. 2007). In contrast, 
heterozygous loss of beclin-1, which also reduces autophagy activity leads to improved 
cardiac function after pressure overload via TAC (Zhu, Tannous et al. 2007). These 
findings suggest that impact of targeting autophagy may be dependent on disease state 
and differentially affected by specific autophagy proteins. 
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1.4.3 Compartmentalization of protein degradation in cardiac muscle 
Protein degradation mechanisms can selectively act at specific subcellular 
localizations in the cardiomyocyte and may impact disease (Lyon, Lange et al. 2013). 
The cardiomyocyte sarcomere has been shown to be an important site of localized 
protein degradation. For example, muscle ring finger (MURF) proteins, a type of 
ubiquitin-E3 ligase, have been observed at the sarcomere at the M-line and Z-disc in 
cardiomyocytes (Spencer, Eliazer et al. 2000, Centner, Yano et al. 2001, Kedar, 
McDonough et al. 2004). Yeast-two-hybrid analyses have demonstrated interactions 
between the three MURF family members, MURF1, 2, and 3, and multiple sarcomeric 
proteins, suggesting that they may participate in their degradation (Spencer, Eliazer et 
al. 2000, Witt, Granzier et al. 2005). Overexpression and loss of function studies in 
cardiomyocytes revealed that MURF1 increases UPS-mediated degradation of the 
sarcomeric protein troponin-I (Kedar, McDonough et al. 2004). Global knockout of 
MURF1 and MURF2 simultaneously leads to cardiac hypertrophy leading to acute heart 
failure and early lethality with underlying defects in Z-disc ultrastructure and upregulation 
of the MURF1 and 2 target proteins, four and a half lim domain 2 (FHL2) and cardiac 
ankyrin repeat protein (CARP) (Witt, Witt et al. 2008). MURF3 global knockout mice do 
not exhibit a phenotype at baseline; however, these mice are predisposed to cardiac 
rupture after myocardial infraction with underlying upregulation of the MURF3 targets, 
FHL2 and γ-filamin (Fielitz, van Rooij et al. 2007). These findings emphasize the 
importance of sarcomere localized protein degradation components in maintenance of 
sarcomere and cardiac function. 
 The specialized cardiomyocyte cell membrane, the sarcolemma, is also a site of 
protein degradation. In neonatal rat cardiomyocytes, the E3 ligase, Casitas b-lineage 
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lymphoma (c-Cbl), has been observed at focal adhesion sites (Rafiq, Guo et al. 2012). 
Furthermore, by activating c-Cbl activity through stimulation with the neutrophil-derived 
serine protease, cathepsin G, the focal adhesion complex proteins, paxilin and focal 
adhesion kinase (FAK) were degraded (Rafiq, Guo et al. 2012). This effect could be 
restored with proteasomal inhibitors (Rafiq, Guo et al. 2012). Altogether these data 
suggested that the cardiomyocyte harbors molecular machinery that is directed to 
perform protein degradation functions at specific subcellular sites in order to mediate 
targeted protein degradation. 
 
1.4.4 ICD as a site of protein degradation that may have importance in cardiac disease  
There is evidence that the ICD is also an active site for protein degradation as 
ubiquitin conjugates, p62 and autophagosomes, were shown to accumulate at the ICD in 
cardiomyocytes in both healthy and diseased settings (Hilenski, Terracio et al. 1992, 
Nepomnyashchikh, Lushnikova et al. 2000, Lange, Xiang et al. 2005, Balasubramanian, 
Mani et al. 2006, Hirschy, Croquelois et al. 2010). In addition, members of the ICD 
complex can be targeted by UPS-related protein degradation mechanisms. In an in vitro 
study in PKP2-deficient rat cardiomyocytes, DSP loss can be restored by protein 
degradation inhibition using the proteasome inhibitor MG132 (Dubash, Kam et al. 2016), 
suggesting that desmosomal proteins are targeted by protein degradation mechanisms. 
Furthermore, β-catenin is an established target of the UPS, though this has only been 
shown for cytosolic β-catenin and not junctional β-catenin (Wu, Xu et al. 2003). 
Degradation of cytosolic β-catenin is thought to regulate its transcriptional activity as part 
of the Wnt/β-catenin signaling pathway, which has been implicated in cardiac 
differentiation and diseases such as heart failure and ARVC (17609106, 14613867). 
Cx43, the major component of gap junctions in the myocardium, can be regulated in 
      
 
30 
stressed cardiomyocytes by autophagy (Su and Lau 2012, Basheer, Harris et al. 2015). 
In cardiomyocytes, chemical and genetic inhibitors of autophagy are able to rescue 
ischemia-induced loss of Cx43, suggesting that Cx43 is degraded through autophagy 
under these conditions (Martins-Marques, Catarino et al. 2015, Martins-Marques, 
Catarino et al. 2015). WW domain containing E3 ubiquitin ligase 1 (WWP1) is the E3 
ligase thought to target Cx43. Global transgenic overexpression of WWP1 in mice lead 
to left ventricular hypertrophy and ventricular arrhythmias with underlying Cx43 loss 
(Basheer, Harris et al. 2015), suggesting that protein degradation control is required for 
Cx43 homeostasis and function. Altogether these data suggest that the ICD complex 
and proteins are under protein degradation control; however, to date, there exists limited 
biological information on the molecular machinery that are important in driving their 
degradation. 
ARVC is a disease associated with specific loss/dysregulation of desmosomal 
proteins (Basso, Czarnowska et al. 2006, Bhuiyan, Jongbloed et al. 2009, Bao, Wang et 
al. 2013). Although the impact of protein degradation mechanisms has not been 
investigated in the context of ARVC and the desmosome, several pieces of evidence 
warrant further studies in this area. First, ARVC is a cardiac disease of the desmosome, 
where desmosomal protein loss is a key molecular feature of the disease. Second, a 
recent study investigating mechanisms underlying ARVC-associated mutations in 
desmocollin 2 suggested that these mutations prevented proper proteolytic cleavage and 
maturation of DSC2 leading to reduced levels of functional DSC2 (Gehmlich, Syrris et al. 
2011), highlighting a potential impact on faulty protein turnover. Third, in PKP2-deficient 
cardiomyocytes in vitro, which exhibit ARVC-associated electrical defects in vivo, exhibit 
DSP protein loss that could be restored by proteasomal inhibition (Dubash, Kam et al. 
2016). These studies suggest that defects in protein turnover/processing mechanisms 
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may contribute to desmosomal protein loss. Altogether this highlights the need for 
research to better understand protein-protein interactions and protein regulatory 
mechanisms at the desmosome, which may provide unique insights on the 
compartmentalized disease features encompassed by diseases of the ICD, such as 
ARVC. 
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1.5 Rationale, Hypothesis, and Specific Aims  
ARVC is a genetic-based heart disease characterized by ventricular dysfunction, 
fibrofatty replacement, and ventricular arrhythmias leading to sudden death. Human 
genetic studies have linked up to 30-60% ARVC cases to mutations in classic genes 
encoding components of the desmosome, a type of cell-cell junction, thus ARVC is 
termed a cardiac disease of the desmosome. The first desmosomal gene linked to 
autosomal dominant ARVC was DSP (Rampazzo, Nava et al. 2002). DSP is a central 
protein in the desmosomal complex that connects the intermediate filament network to 
the core of the desmosomal complex through interactions with its C-terminus. DSP binds 
to the armadillo proteins and desmosomal cadherins through its N-terminus. Thus, the 
N-terminal region is thought to be a “hotspot” for desmosomal protein interactions as 
well as common site for ARVC-associated mutations, which can be a potential region of 
DSP to uncover novel protein interactions to better understand ARVC disease 
pathogenesis.  
To better understand the role of DSP in mechanisms driving ARVC, our 
laboratory developed a novel mouse model of a biventricular form of ARVC through 
cardiomyocyte specific ablation of DSP (Lyon, Mezzano et al. 2014) that recapitulates all 
major human ARVC electrical and structural disease features. Our studies along with 
others demonstrate that desmosomal protein loss is considered a molecular hallmark of 
ARVC. Recent evidence highlights the intercalated disc as a site of protein degradation. 
Moreover, in vitro studies in cardiomyocytes suggest that DSP can be targeted by 
protein degradation mechanisms, however the mechanisms controlling desmosomal 
protein degradation remain uncharacterized. By targeting DSP in an unbiased protein 
interaction screen, we will have the potential to identify proteins that interact with the 
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desmosome and that may affect protein turnover mechanisms and contribute to ARVC 
pathogenesis. 
 
Hypothesis: 
There exist novel proteins at the cardiac desmosome that regulate protein degradation, 
and dysregulation of these pathways may drive cardiac defects in desmosomal 
diseases, such as ARVC. 
 
Specific Aims: 
1.1 To screen for novel cardiac N-terminal DSP-interacting proteins using an unbiased 
yeast-2-hybrid screen with an adult human heart cDNA library, identify a candidate 
protein that may impact protein degradation, and validate its expression in DSP-deficient 
models. 
1.2 To determine the role of this novel DSP- interacting protein in cardiomyocytes and 
protein degradation through generation of cardiomyocyte-specific mouse model and 
cells. 
1.3 To determine whether the cardiac protein degradation mechanisms associated with 
this novel DSP-interacting protein are similarly impacted in a mouse model of ARVC and 
other models of human disease. 
 
The results of these studies are presented in chapters 3-6 and are discussed in terms of 
their implications on cardiac desmosomal biology and mechanisms impacting ARVC. 
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Figure 1. Diagram of cardiac intercalated disc proteins and complexes. 
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Table 1. Knockout Mouse Models of ARVC. 
 
Protein 
Model Type/ 
Zygosity 
Cre 
Promoter Cardiac Features 
Ultrastructural 
Features Reference 
DSP Cardiac Specific/ 
Heterozygous 
aMHC-Cre Left ventricular 
dysfunction, fibrofatty 
accumulation and both 
spontaneous and induced 
arrhythmias 
Desmosomal 
defects 
Garcia-
Gras et al., 
2006 
  Cardiac Specific/ 
Homozygous 
Mlc2v-Cre Biventricular dysfunction, 
fibrofatty accumulation, 
both spontaneous and 
induced ventricular 
arrhythmias and 
premature death 
ICD defects Lyon et al., 
2014 
  Cardiac Specific/ 
Heterozygous 
Nkx2.5-Cre Left ventricular 
dysfunction and fibrofatty 
accumulation 
Not examined Lombardi et 
al., 2009 
  Cardiac Specific/ 
Heterozygous 
Mef2c-Cre Fibrofatty accumulation Not examined Lombardi et 
al., 2009 
PKP2 Global/ 
Heterozygous 
- Drug induced ventricular 
arrhythmias 
Lower 
desmosome 
abundance; ICD 
membrane 
defects 
Cerrone et 
al., 2012 
JUP Global/ 
Heterozygous 
- Right ventricular 
dysfunction and both 
spontaneous and induced 
ventricular arrhythmias 
None Kirchhof et 
al., 2006 
  Cardiac Specific/ 
Homozygous 
aMHC-Cre Ventricular dysfunction, 
fibrosis and ventricular 
arrhythmias 
ICD defects Li et al., 
2011 
  Cardiac Specific/ 
Homozygous 
aMHC-
mER-Cre-
mER 
Ventricular dysfunction, 
fibrosis 
ICD defects Li et al., 
2011 
DSG2 Cardiac Specific/ 
Homozygous 
aMHC-Cre Chamber dilation, 
calcifying cardiomyocyte 
necrosis, aseptic 
inflammation,fibrosis, and 
conduction defects 
ICD defects Kant et al., 
2015 
  Global/ 
Homozygous 
- Left ventricular 
dysfunction and 
biventricular fibrosis; 
electrophysiology and 
fatty accumulation not 
examined 
Not examined Chelko et 
al., 2016 
iASSP Global/ 
Homozygous 
- Embryonic right 
ventricular wall thinning 
and dilatation; Adult 
biventricular dysfunction, 
fibrofatty accumulation, 
ventricular arrhythmias 
and sudden death 
Desmosomal 
defects 
Notari et 
al., 2015 
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Table 2. Knockin and Transgenic Mouse Models of ARVC. 
 
Protein Model Type Mutation Cardiac Features 
Ultrastructural 
Features Reference 
DSP Cardiac-
Specific 
Transgenic 
Human 
DSP 
R2834H 
Biventricular 
dysfunction and 
fibrofatty accumulation 
ICD defects Yang et al., 
2006 
  Cardiac-
Specific 
Transgenic 
Human 
DSP V30M 
Embryonic lethal at 
E13.5  
Not examined Yang et al., 
2006 
  Cardiac-
Specific 
Transgenic 
Human 
DSP Q90R 
Embryonic lethal at 
E13.5  
Not examined Yang et al., 
2006 
PKP2 Viral 
Transmission 
Human 
PKP2 
R735X 
Exercise induced right 
ventricular dysfunction 
No 
ultrastructural 
defects 
Cruz et al., 
2015 
  Cardiac-
Specific 
Transgenic 
Mouse 
PKP2 aa 
1-329 
Left ventricular 
dysfunction, inducible 
arrhythmias 
ICD defects Moncayo-
Arlandi et al., 
2016 
JUP Global Knock 
In 
Mouse 
Naxos JUP 
Perinatal lethality 
without cardiac defects 
Not examined Zhang et al., 
2015 
  Global Knock 
In 
Stabilized 
Mouse 
Naxos JUP 
No phenotype Not examined Zhang et al., 
2015 
  Cardiac-
Specific 
Transgenic 
Flag-WT Fibrofatty accumulation 
without functional 
defects; 
electrophysiology not 
examined 
None Lombardi et al., 
2009 
  Cardiac-
Specific 
Transgenic 
Mouse 
3xFlag-WT 
Fibrofatty accumulation, 
cardiac arrhythmias and 
sudden death with no 
functional defects 
Not examined Lombardi et al., 
2011 
  Cardiac-
Specific 
Transgenic 
Mouse 
Naxos JUP 
Left ventricular 
dysfunction, fibrofatty 
accumulation, and 
cardiac arrhythmias 
Not examined Lombardi et al., 
2011 
DSG2 Global Knock 
In 
EC1/EC2 
Deletion 
Left and right ventricular 
dilatation, fibrosis, 
calcification, and 
spontaneous death 
ICD defects Krusche et al., 
2011;  Kant et 
al., 2012 
  Cardiac-
Specific 
Transgenic 
Mouse 
DSG2 
N271S 
Spontaneous ventricular 
arrhythmias, conduction 
slowing, ventricular 
dilatation and 
aneurysms, and 
replacement fibrosis 
leading to sudden 
cardiac death  
None Pilichou et al., 
2009 
TTN Global Knock 
In 
T2850I Left ventricular diastolic 
dysfunction  
Not examined Bogomolovas et 
al., 2016 
Rho-
Kinase 
Smooth 
Muscle-
Specific 
Transgenic 
Dominant 
Negative 
RB/PH 
(TT) 
Cardiac dysfunction, 
fibrofatty accumulation, 
ventricular arrhythmias, 
and sudden death 
ICD defects Ellawindy et al., 
2015 
 Cardiac-
Specific 
Transgenic 
Dominant 
Negative 
RB/PH 
(TT) 
No phenotype Not examined Ellawindy et al., 
2015 
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2.1 Yeast-2-hybrid 
All DNA fragments used for yeast-2-hybrid and forced yeast-2-hybrid analysis 
were amplified using PCR and cloned into pGBKT7 (bait plasmid) or pGADT7 (prey 
plasmid) and used in the mating yeast strains Y2HGold (bait strain, Clontech) or Y187 
(prey strain). For yeast-2-hybrid screen, DSP bait containing yeast were mated with an 
adult human heart cDNA library (Mate n Plate Library, Clontech). Mated yeast were 
assayed for growth and β-galactosidase activity on selection plates. Library plasmid 
sequences from positive clones were PCR amplified and sequenced. To confirm 
interactions and search for minimal binding sites in a forced yeast-2-hybrid assay, bait 
and prey yeast were mated and assayed for beta-galactosidase activity according to 
manufacturer’s instructions (Thermo Fisher). For detailed information on yeast methods 
and protocols refer to the yeast protocols handbook available on the Clontech 
homepage (www.clontech.com). 
 
2.2 Protein expression analysis 
2.2.1 Western blot 
Neonatal and embryonic whole heart or adult ventricles were dissected, snap 
frozen in liquid nitrogen. Samples were then homogenized by polytron blade in 1% 
Triton-X buffer (Yang, Bowles et al. 2006). Intercalated disc enriched fractions were 
generated by centrifugation at 20,000g for 30 minutes followed by solubilization of 
Triton-X insoluble fraction in high detergent lysis buffer (NuPage LDS Buffer, Life 
Technologies). Equivalent amounts of protein were run on 4-12%-gradient BisTris 
polyacrylamide minigels using the NuPAGE buffer system (Life Technologies). The 
proteins were blotted overnight onto nitrocellulose. After correct transfer had been 
established by Ponceau red staining (Sigma-Aldrich), membranes were blocked by 
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incubation in 10% nonfat dry milk in washing buffer (0.9% NaCl, 9 mM Tris, pH 7.4, 0.1% 
Tween-20) for 1 h at RT. Blocked membranes were incubated with primary antibody 
overnight, washed three times in washing buffer, incubated with secondary HRP 
conjugated antibody for two hours, washed three times, and visualized with ECL 
substrate (Thermo-Fisher). Primary antibody dilution were a follows: SNAP29 (rabbit, 
1:1000, Synaptic Systems), DSP (mouse, 1:1000, AbD Serotec), PKP2 (rabbit, 1:1000, 
Fitzgerald), JUP (goat, 1:1000, Sigma-Aldrich), DSC2 (rabbit, 1:1000, Fitzgerald), DSG 
1/2 (mouse, 1:1000, Fitzgerald), Cx43 (rabbit, 1:5000, Sigma-Aldrich), NCAD (rabbit, 
1:1000, Abcam), LC3A/B (rabbit, 1:1000, Cell Signaling), p62 (guinea pig, 1:1000, 
Progen), GAPDH (mouse, 1:5000, Santa Cruz Biotechnology), b-Actin (mouse, 1:5000, 
Sigma-Aldrich). Results from the chemiluminescence reaction were visualized on x-ray 
films. The figures show representative blots performed with extracts from one individual 
animal; the experiments were repeated at least two times with extracts from at least 
three different animals. 
 
2.2.2 Immunostaining 
Mouse heart cryosections were fixed in 100% acetone at −20°C and stained with 
primary antibodies against SNAP29 (rabbit, 1:100, Synaptic Systems), DSP (mouse, 
1:100, AbD Serotec), NCAD (rabbit, 1:100, Abcam), perilipin (rabbit, 1:100, Cell 
Signaling), JUP (mouse, 1:100, Sigma-Aldrich; goat, 1:100, Santa Cruz Biotechnology), 
Cx43 (rabbit, 1:100, Invitrogen) sarcomeric α-actinin (mouse, 1:200, Sigma-Aldrich), 
LC3B (rabbit, 1:100, Cell Signaling). Sections and cells were subsequently stained with 
fluorescently labeled secondary antibodies (1:100, Jackson ImmunoResearch Inc.) and 
Hoescht nuclear stain in cases where indicated, followed by imaging using confocal 
microscopy (Olympus FV1000). 
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2.3 Mouse Models 
DSP cardiac specific knockout (DSP-cKO) mice were previously generated and 
characterized (24108106). SNAP29 “knock-in first with conditional potential” (SNAP29-
gKO) mice wer(Klionsky, Abdelmohsen et al. 2016)e obtained from the European Mutant 
Mouse Archive (EMMA). To generate the cardiac specific SNAP29 knockout mouse line, 
SNAP29-gKO mice were first bred with the flippase mouse line to remove the knockout 
cassette, then bred with the cardiac specific Xenopus myosin light chain 2- (XMLC2) Cre 
mouse line (Breckenridge, Kotecha et al. 2007). Controls for mouse studies were age 
matched and litter matched wildtype mice for SNAP29-gKO studies or SNAP29flox/flox 
Cre negative mice for SNAP29-cKO studies. All physiological studies were performed on 
male mice only. Mice were fed food and water ad libitum. A 24-hour diurnal light cycle 
was maintained, with standard 12-hour-on and off cycles. For experimental studies, adult 
mice were sacrificed by cervical dislocation following anesthesia by intraperitoneal 
injection of a mixture of ketamine (100 mg/kg) and xylazine (5 mg/kg), while the depth of 
anesthesia was monitored by toe pinch. Neonatal mice were sacrificed by decapitation. 
All animal procedures were in full compliance with the guidelines approved by the 
University of California-San Diego Animal Care and Use Committee and carried out in 
accordance with the Guide for the Care and Use of Laboratory Animals of the National 
Institutes of Health. 
 
2.4 Generation of hiPSC-derived cardiomyocytes 
hiPSCs were differentiated under a previously reported fully defined small 
molecule-based protocol (Lian, Zhang et al. 2013, Zanella and Sheikh 2016). Briefly, 
hiPSCs were washed once with RPMI medium before initial 48h treatment with 6µM 
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CHIR90021-HCl (Selleck Chemicals) in RPMI medium supplemented with B27 
containing insulin (Life Technologies). Subsequently cells were washed once with RPMI 
medium and switched to RPMI medium supplemented with B27 without insulin (Life 
Technologies) and were maintained in that media for 48h. 96h after initiation conditioned 
medium generated by differentiating cells was combined at a 1:1 ratio with RPMI 
medium and B27 without insulin, supplemented with 5µM IWP-2 (Cayman Chemicals) 
and used to treat cells for 48h. Media were  changed thereafter according to the time 
points established in the published protocol. On day 30 cells were switched to 75% 
DMEM and 25%M199 supplemented with B27 supplement containing insulin and were 
maintained in this medium composition until day 60. 
 
2.5 In vitro knockout of SNAP29 
Cardiomyocytes were prepared from 1-2 day old mice as previously described 
(Lyon, Mezzano et al. 2014). Adenovirus vectors containing the lacZ (AdLac-Z) and Cre 
recombinase (AdCre) cDNAs were prepared (UCSD Viral Vector Core) and used at 
multiplicity of infection 100 pfu/cell. Neonatal ventricular cardiac myocytes isolated from 
SNAP29-floxed mice were plated on laminin and infected with AdLacZ and AdCre, 2 
days following isolation. Viral particle carrying medium was changed from cells after 24 
h, and cells were subsequently maintained in a media consisting of DMEM, M199, 5% 
fetal bovine serum, 10% horse serum and 1% penicillin/streptomycin/glutamine for the 
duration of the study. To control for effects of variable baseline autophagy, cells 
cardiomyocytes were serum and glucose starved for 2 hours and returned to complete 
media for two hours prior to analysis. Cardiomyocytes were analyzed 48 hours post-
infection. 
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2.6 In vitro contractility and electrophysiology measurement  
Neonatal mouse cardiomyocytes were isolated as above and seeded on laminin 
coated E-Plate CardioECR 48 and infected with adenovirus as above. Media were 
refreshed with 90 µl of pre-warmed hiPSC-CMs maintenance medium at least 4 h prior 
to compound addition. 10 µl of compound solutions were added to the wells in a single 
dose per well mode. xCELLigence® RTCA CardioECR system (ACEA Biosciences, Inc.) 
was used to monitor cardiomyocyte attachment, viability, contraction and field potential 
(FP) from spontaneously beating hiPSC-CMs. Impedance (IMP) data were sampled at 2 
ms (500 Hz), while FP data were collected at 0.1 ms (10 K Hz) with a bandwidth of 1 Hz 
to 3 KHz. Data acquisition is controlled by xCELLigence® RTCA CardioECR Data 
Acquisition software. In a typical experiment, a 30-min baseline of IMP and FP signals 
was taken by sampling hiPSC-CMs every 5 min for 20 or 60 s. Cells were then treated 
with vehicle control and studied compounds. The cell responses to compound were 
captured by measuring both IMP and FP signals every 2 min for 20 or 60 s during the 
first 1 h to evaluate short-term effects of compounds. 
 Raw data collected from IMP electrodes and ECR electrodes were analyzed 
offline using xCELLigence® RTCA CardioECR Data Analysis software. In order to 
analyze the complex wave forms derived from hiPSC-CMs contractility and FP 
responses, which is a measure of integrated ion channel activity, a number of 
parameters were derived. Contractility signal was evaluated by the beating rate (BR), 
beating period (BP) and beating amplitude (BAmp) parameters. Beating rate is defined 
as the number of beats per unit of time and is expressed as beats/min. Beating period 
defines the time period between two successive major peaks. BAmp is defined as the 
absolute (delta) Cell Index (CI) value between lowest and highest points within a beating 
waveform. For analysis of FP signal, the FP spike amplitude (FPAmp) is derived, which 
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is the absolute (delta) value in mV from lowest point of the initial spike to the highest 
point of the spike. The FP Duration (FPD) is defined as the time period between the 
negative peak of the FP spike to the maximum or minimum point of the reference wave. 
The reference wave can be negative or positive depending on how the cardiomyocytes 
are situated with respect to the FP electrodes. 
 
2.7 In vitro autophagic flux measurement  
Cells were transduced for overnight with BacMam GFP-LC3B (Life technologies). 
Cell were incubated with Lysotracker Far Red (Life Technologies) 30 minutes prior to 
analysis according to manufacturer details. Cells were imaged live by confocal 
microscopy (Olympus FV1000) 48 hours after Adeno-Cre or Adeno-LacZ infection. 
 
2.8 Cardiac physiology measurement  
2.8.1 Echocardiography 
Animals are anesthetized with 5% isoflurane for 30 seconds and then maintained 
at 0.5% throughout the examination.  The anterior chest wall is shaved and then Nair is 
applied to remove any remaining hair.  Small needle electrodes for simultaneous 
electrocardiogram are inserted into one upper and one lower limb.  Transthoracic 
echocardiography (M-mode and 2-dimensional echocardiography) is performed using 
the FUJIFILM VisualSonics Inc., Vevo 2100 high-resolution ultrasound system with a 
linear transducer of 32-55MHz.  Measurements of chamber dimensions and wall 
thicknesses are performed. Percentage fractional shortening (%FS) is used as an 
indicator of systolic cardiac function. 
 
2.8.2 Surface electrocardiography 
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Adult (3 months old) mice were anesthetized with 1% isoflurane. Needle 
electrodes (30 gauge) were inserted subcutaneously into right forearm and left leg. ECG 
signals were amplified using Warner Instruments DP-304 Differential Amplifier bandpass 
filtered between 0.1 and 100 Hz. Signal was further filtered through a Quest Scientific 
HumBug 50/60 Hz Noise Eliminator and digitized at 3000 Hz. 
 
2.8.3 Telemetry ECG 
Conscious ECG telemetry using an implantable wireless transmitter/receiver 
system (Data Sciences International/Ponemah) was performed on mice as previously 
described (Lyon, Mezzano et al. 2014). For implantation procedures mice were 
anesthetized with isoflurane (5%for induction, 1.5-2.5% for maintenance in 100% 
oxygen) and monitored continuously. Under the stereomicroscope, a radio transmitter 
(TA10ETA-F20; Datasciences) was inserted subcutaneously at the subscapular thoracic 
region and secured via sutures to the muscular fascia and skin. Two leads were 
tunneled through the subcutaneous space cranially and caudally. Transmitters were 
detected by receiver platforms, placed directly underneath the animal’s cage, which 
were linked to an immediately adjacent computer. DataquestART2.0 data acquisition 
software (Data Sciences International) was used for digitization of the signal (at a 
sampling rate of 1000 Hz). Studies were recorded continuously for 72 h following 1 week 
recovery from the implantation. Premature beat analysis was performed on LabChart® 
(ADInstruments) by manual inspection of ECG telemetry traces. Premature beats were 
defined as a QRS originating early and without a P-wave. Interbeat interval variability 
analyses were performed on LabChart® (ADInstruments). Twenty minutes of recorded 
telemetry ECGs were analyzed using the heart rate variability module. Traces were 
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manually inspected to check for R wave detection accuracy and artifacts (R-R intervals 
shorter than 20 msec and longer than 600 msec) were excluded. 
 
2.8.4 Ventricular tachycardia induction 
Invasive intracardiac electrophysiology was studied in adult mice (3 months old) 
following a previously established protocol with some modifications (Hong, Yang et al. 
2014). Mice were anesthetized with 1.5% isoflurane in 100% oxygen; body temperature 
was maintained at 37 °C with a heating pad; and respiration was maintained using a 
respirator connected to an endotracheal tube placed into the mouse trachea. ECGs were 
recorded using PowerLab (ADInstruments) during the whole experimental procedure. 
After lateral thoracotomy, the heart was visualized, and an 8-electrode catheter was 
inserted into the heart through the superior vena cava for pacing. A constant current 
stimulus isolator (FE180, ADInstruments, Colorado Springs, CO) was used to deliver 
pacing currents, which was interfaced with a software-driven programmed electrical 
stimulator (LabChart Pro, ADInstruments, Colorado Springs, CO). Pacing thresholds 
were then determined, and stimulation was delivered at a 0.3- to 0.4-ms pulse width at 
twice the capture threshold. Standard single, double, and triple extrastimulations were 
performed. A drive cycle length of 100 ms (S1) was followed by S2 decremented by 2 
ms until the ventricular effective refractory period was reached. After this, a train of 
programmed stimulation with one, two, or three extra stimuli after S1 (S1–S4) was 
performed and repeated every 1 s for 30 min to determine the incidence and frequency 
of induced VT. After baseline experiments, isoproterenol (2.5 mg kg−1 body weight) was 
injected i.p., and 1 min was allowed to elapse for stabilization of heart rate before the 
same S1–S4 pacing protocol was repeated. Nonsustained VT was defined as four to 
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nine consecutive beats, and sustained VT was defined as >9 QRS complexes not 
preceded by supraventricular activity. LabChart was used for data analysis. 
 
2.9 Cardiac histological analysis 
Whole hearts were paraffin embedded and 10µM transverse sections were 
obtained sequentially. Sections were stained with hematoxylin and eosin or Masson’s 
trichrome (Sigma–Aldrich, St. Louis, MO, USA) according to manufacturer’s instructions. 
For oil red O staining, hearts were embedded in OCT and 10mm sectioned were 
obtained sequentially. Sections were stained for oil red O and mounted in fluorescent 
mounting medium. Sections were imaged using the NanoZoomer 2.OHT Slide Scanning 
system (Hamamatsu, Hamamatsu City, Japan). 
 
2.10 Ultrastructural Analysis 
Deeply anesthetized adult mice were cervically dislocated and perfused with a 
fixation buffer containing 2% paraformaldehyde and 2.5% glutaraldehyde in 0.15 M 
sodium cacodylate buffered to pH 7.4. Fixed hearts were excised and only right and left 
ventricular free walls were processed for electron microscopy as previously described. 
Ultrathin sections were subsequently stained with 2% uranyl acetate and Sato lead as 
previously described. Electron micrograph images were obtained with a FEI Tecnai Spirit 
G2 BioTWIN transmission electron microscope. 
 
2.11 Statistical analysis 
Data presented in the text and figures are expressed as mean values ± SEM. 
Significance was evaluated by two-tailed Student's t-test or repeated-measures ANOVA. 
Significance of categorical data was evaluated for significance by Pearson’s chi-squared 
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test. For Kaplan–Meier survival analysis, significance was evaluated by the log-rank test. 
P < 0.05 was considered statistically significant. 
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3.1 SNAP29 is a novel DSP interacting protein 
To identify novel DSP-interacting protein in the heart, a yeast-2-hybrid screen 
was performed using DSP as bait. The N-terminal region of DSP has been previously 
shown to interact with other desmosomal proteins and was therefore selected to perform 
the interaction screen. Human DSP cDNA coding for amino acids 500-1030 was cloned 
into the yeast bait expression vector, pGBKT7 (Fig. 2A) and transformed into the 
Y2HGold mating strain. The DSP bait was screened against an adult human heart cDNA 
library in a yeast-2-hybrid mating system. Four selection markers were used to identify 
positive clones: (i) histidine production, (ii) adenine production, (iii) β-galactosidase 
activity, and (iv) aureobasidin A resistance. 44 colonies grew and turned blue on 
quadruple drop out media; all colonies were sequenced. Full length Synaptosomal 
associated protein 29 (SNAP29) (Fig. 2B) was identified during screening of positive 
clones. Previous studies have identified a link between SNAP29 and protein degradation 
mechanisms, specifically autophagy (Itakura, Kishi-Itakura et al. 2012) suggesting that it 
could have an effect on desmosomal protein degradation mechanisms.  
 To confirm the direct interaction between DSP and SNAP29, forced yeast 2-
hybrid was performed with the original DSP N-terminus bait and full length SNAP29 as 
prey. β-galactosidase activity quantification revealed significantly higher activity and 
therefore interaction between DSP and SNAP29 compared to negative controls (Fig. 
2C). To determine if SNAP29 colocalizes endogenously with DSP in the heart, 
immunofluorescence microscopy was performed on ventricular tissue sections from 
adult mouse and human hearts and revealed SNAP29 present with DSP at the ICD (Fig. 
3). 
 
3.2 SNAP29 expression is reduced in DSP deficient models 
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3.2.1 SNAP29 expression is reduced in a desmoplakin-deficient mouse model 
To determine whether the localization of SNAP29 at the ICD in vivo requires 
DSP, ventricular heart tissue from our biventricular mouse model of ARVC caused by 
cardiac specific loss of DSP (DSP-cKO) (Lyon, Mezzano et al. 2014) was analyzed for 
SNAP29 expression. Immunofluorescence microscopy performed on DSP-cKO heart 
cryosections revealed the striking loss of SNAP29 from ICDs lacking DSP, which were 
identified by JUP staining, compared to littermate controls (Fig. 4A). Western blot 
analysis of the triton-X100 insoluble fraction which is ICD-enriched in adult DSP-cKO 
mouse hearts revealed that SNAP29 is significantly reduced (%, n=3) (Fig. 4B). These 
results suggest a molecular link between SNAP29 and DSP at the cardiac ICD. 
 
3.2.2 SNAP29 expression is reduced in ARVC hiPSC derived cardiomyocytes 
To interrogate SNAP29 expression in a human setting, human induced 
pluripotent stem cell derived cardiomyocytes (hiPSC-CMs) were generated from patients 
with ARVC harboring desmosomal protein mutations as well as from non-diseased 
human samples. The three hiPSC-CM lines analyzed were ARVC-PKP2 (c.1171-2A>G), 
ARVC-DSG2 (c.1498C>A), and Control. Western blot analysis of these cell lines 
revealed striking loss of SNAP29 specifically in PKP2-mutant hiPSC-CMs which also 
were deficient in desmosomal protein expression (Fig. 4C). Interestingly, SNAP29 
expression was not reduced in DSG2-mutant hiPSC-CMs (Fig. 4C). These findings 
suggest that SNAP29 expression may be dependent on desmosomal protein expression 
in human cardiomyocytes. 
 
Chapters 3-6, in part are currently being prepared for submission for publication 
of the material. Pellman, Jason; Lyon, Robert; Liang, Yan; Mezzano, Valeria; Zanella, 
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Figure 2. Identification of the novel cardiac desmosomal interacting protein 
SNAP29 in a yeast-2-hybrid screen using DSP as bait. (A) Diagram of DSP with 
region of N-terminus (amino acids 500-1030) used for construction of bait plasmid DSP-
F2 in pGBKT7. (B) Diagram of full length SNAP29 region identified in yeast-2-hybrid 
screen using DSP-F2 as bait. (C) Assay of β-galactosidase reporter activity in mated 
yeast expressing DSP-F2 and SNAP29 yeast-2-hybrid constructs. DSP-F2 mated with 
empty prey vector (pGADT7) and SNAP29 mated with empty bait vector (pGBKT7) are 
negative controls. * = p<0.05   
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Figure 3. SNAP29 colocalizes with DSP at the ICD in adult mouse and human 
hearts. Immunofluorescence staining of SNAP29 and DSP in 2-month-old wildtype 
mouse heart ventricular or adult human heart ventricular cryosections were stained with 
antibodies against SNAP29 (red) and DSP (green) and counterstained with DAPI (blue). 
White arrowheads mark colocalization at ICDs. Scale bar = 10 µm 
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Figure 4. SNAP29 expression is reduced in a DSP-deficient mouse model and a 
hiPSC-derived cardiomyocyte model. (A) Immunofluorescence staining of 6-week-old 
hearts from DSP-cKO mice for SNAP29 (red), DSP (green), and JUP (white) and 
counterstained with DAPI (blue). (B) Western blot analysis of insoluble fraction of 6-
week-old hearts from DSP-cKO mice for SNAP29 and DSP. Tubulin was used as a 
loading control. (C) Western blot analysis of cell lysates from hiPSC-derived 
cardiomyocytes from control and ARVC patient (ARVC-DSG2 and ARVC-PKP2) donors. 
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Chapter 4 The Effects of Cardiomyocyte-Specific Loss of SNAP29 in Mouse in vivo   
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4.1 Cardiac Characterization of a Cardiac-Specific SNAP29 Knockout (SNAP29-cKO) 
Mouse 
4.1.1 SNAP29 expression is reduced in adult SNAP29-cKO mouse hearts 
To determine the effects of cardiac specific loss of SNAP29, SNAP29-floxed 
mice (Fig. 5A) were crossed with the early and cardiac specific Xenopus myosin light 
chain 2-Cre recombinase (XMLC2-Cre) mouse line (Breckenridge, Kotecha et al. 2007). 
A breeding strategy was utilized to generate homozygous SNAP29-cKO 
(SNAP29flox/flox;XMLC2-Cre+), heterozygous SNAP29-cKO (SNAP29wt/flox;XMLC2-
Cre+) and littermate controls (SNAP29flox/flox;XMLC2-Cre-) (Fig. 5B). Homozygous 
SNAP29-cKO and littermate control mice are used for all studies. SNAP29-cKO mice are 
born at Mendelian ratios (data not shown) and survive to adulthood but exhibit 
preliminary evidence of premature death at 9 months of age (Fig. 5C). To determine the 
efficiency of knock out in SNAP29-cKO hearts, western blot analysis was performed on 
hearts from 1 month old mice. A significant reduction (64±6%, p <0.05) in SNAP29 levels 
was observed in whole ventricle samples (Fig. 5D). 
 
4.1.2 SNAP29-cKO mice exhibit baseline and inducible ventricular arrhythmias 
To determine whether SNAP29-cKO mice exhibit the characteristic ventricular 
arrhythmias of ARVC (Haugaa, Haland et al. 2016), telemetry electrocardiography 
(ECG) was performed on conscious and freely moving 3-month-old mice. Analysis of 
ECG recordings revealed significantly higher rates of spontaneous premature ventricular 
contractions (PVCs) in SNAP29-cKO mice compared to littermate controls (Fig. 6A). 
This parallels the high rates of PVCs observed in patients with ARVC (Sen-Chowdhry, 
Syrris et al. 2007, Thiene, Corrado et al. 2007). 
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To determine whether SNAP29-cKO mice exhibit the inducible ventricular 
arrhythmias characteristic of ARVC, 3 month old SNAP29-cKO were subjected to 
intracardiac ventricular burst pacing. As is evident from representative ECG recording, 
sinus rhythm resumed immediately after ectopic pacing in WT mice (Fig. 6B). However, 
sustained monomorphic ventricular tachycardia (VT) ensued after pacing in SNAP29-
cKO hearts (Fig. 6B). VT was significantly more inducible in SNAP29-cKO mice 
compared to littermate controls (Fig. 6B). In patients with ARVC, VT inducibility is 
associated with increased risk of future adverse cardiac events (Saguner, Medeiros-
Domingo et al. 2013), suggesting that the hearts of SNAP29-cKO mice may be more 
disease prone 
 
4.1.3 SNAP29-cKO mice exhibit lipid accumulation in right ventricle 
To determine whether SNAP29-cKO mouse hearts display the fatty accumulation 
observed in human ARVC (Fujita, Terasaki et al. 2008), oil red O staining was 
performed. Punctate oil red O staining was observed in cardiomyocytes throughout the 
right ventricle of SNAP29-cKO hearts and not in littermate controls (Fig. 7). Oil red O 
staining was not observed in the left ventricle or either atrium (Fig. 7). 
 
4.1.4 Cardiac morphology, fibrosis, and function are not affected by cardiomyocyte loss 
of SNAP29 
To determine whether SNAP29-cKO mice displayed other hallmarks of ARVC, 
SNAP29-cKO mice were assessed for morphological, histological, and functional 
features of ARVC. At 3 months of age, morphological analysis of SNAP29-cKO hearts 
revealed no significant differences from littermate controls in terms of gross morphology 
(Fig. 8A), heart weight to body weight ratio or heart weight to tibia length ratio (Fig. 8B). 
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Histological analysis by Masson’s trichrome stain revealed no signs cardiac fibrosis (Fig. 
8C). Transthoracic echocardiography revealed no differences in cardiac parameters or 
function in SNAP29-cKO hearts compared to littermate controls (Fig. 8D). Follow up 
analysis of older mice at 8 months of age also revealed no differences in cardiac 
parameters or morphology compared to littermate controls (Fig. 8D). These findings 
suggest that loss of cardiomyocyte SNAP29 does not contribute to changes in cardiac 
morphology, fibrosis or function. 
 
4.1.5 SNAP29-cKO mice have selectively reduced desmosomal and gap junction 
protein levels 
To determine how loss of SNAP29 in the heart affect ICD protein levels, western 
blot was performed for desmosomal, gap junction, an FAJ proteins in ventricular tissue 
from adult SNAP29-cKO mice. At 3 months of age, a significant reduction in DSP and 
PKP2 was observed, though the remaining desmosomal proteins were not affected (Fig. 
9). Interestingly, the gap junction protein Cx43 was also reduced (Fig. 9). No changes 
were observed in FAJ protein levels (Fig. 9), suggesting loss of SNAP29 leads to 
specific effects on select desmosomal and gap junction proteins. 
 
4.2 Protein Degradation Defects in SNAP29-cKO Heart 
4.2.1 Markers of autophagy accumulate in SNAP29-cKO hearts 
Previous studies in cell lines and fruit fly models have identified a potential role 
for SNAP29 in protein degradation, specifically as a mediator of autophagy (Itakura, 
Kishi-Itakura et al. 2012, Takats, Nagy et al. 2013). To determine how loss of SNAP29 in 
the heart affects autophagy, western blot, immunofluorescence microscopy, and 
transmission electron microscopy analysis were performed. Levels of the UPS-
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autophagy crosstalk protein p62 were increased at 3 months of age (Fig. 10A), 
suggesting an elevated amount of proteins entering the autophagy protein degradation 
pathway. Immunofluorescence analysis further revealed that LC3B was localized at the 
ICD in SNAP29-cKO mouse heart while no LC3B signal was observed in littermate 
controls (Fig. 10B). TEM analysis of these hearts revealed ultrastructural defects at the 
ICD, specifically accumulation of multi-membrane vesicles similar to autophagosomes 
and autolysosomes (Fig. 10B), suggesting that the elevated LC3B is due to ICD-specific 
autophagosome accumulation. 
 
4.2.2 Characterization of protein degradation in a model of ARVC 
To determine whether autophagy is altered in ARVC, hearts from our DSP-cKO 
mouse model of ARVC (Lyon, Mezzano et al. 2014) were analyzed. Western blot 
analysis of DSP-cKO hearts revealed accumulation of LC3B and p62 (Fig. 11A). 
Immunofluorescence microscopy of DSP-cKO ventricular cryosections revealed the 
striking appearance of LC3B specifically at ICDs lacking DSP, which are marked by JUP 
(Fig. 11B). TEM analysis revealed the presence of multi-membrane vesicles similar to 
autophagosomes and autolyososomes specifically at the ICD in DSP-cKO mouse hearts 
and not in controls (Fig. 11B). These findings mirror the effects on autophagy observed 
in SNAP29-cKO hearts (Fig. 10). These findings in addition to the loss of SNAP29 at the 
ICD (Fig. 4A/B) suggest that loss of SNAP29 leads to accumulation of autophagosomes 
specifically at the ICD in DSP-cKO mouse hearts. 
 
4.2.3 Characterization of heart and skin disease-associated DSP mutations 
The region of DSP that SNAP29 binds is known to be a “hotspot” for 
desmosomal interactions and also contains heart and skin disease associated mutations 
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(Smith and Fuchs 1998, Boyden, Kam et al. 2016). The DSP mutations, Q616P and 
H618P, associated with the heart and skin disease erythrokeratodermia-cardiomyopathy 
syndrome (Boyden, Kam et al. 2016) were replicated in the DSP N-terminal yeast 
expression construct used for the initial yeast-2-hybrid screen (Fig. 12A). These 
constructs were tested against wildtype full length SNAP29 (Fig. 12B). β-galactosidase 
activity quantification revealed significantly lower activity between mutant DSP and 
wildtype SNAP29 (Fig. 12C), suggesting that these desmosomal mutations may lead to 
reduced interaction with SNAP29. 
 
Chapters 3-6, in part are currently being prepared for submission for publication 
of the material. Pellman, Jason; Lyon, Robert; Liang, Yan; Mezzano, Valeria; Zanella, 
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Figure 5. Generation, expression, and survival of a novel cardiac specific SNAP29 
knockout (SNAP29-cKO) mouse line. (A) Genetic construct used to generate 
SNAP29-floxed and knockout alleles. (B) Breeding strategy to generate SNAP29-cKO 
(SNAP29flox/flox;XMLC2-Cre+) and littermate control (SNAP29flox/flox;XMLC2-Cre-) 
mice. (C) Kaplan-Meier survival curve for SNAP29-cKO mice and littermate controls. (D) 
Western blot analysis of 1-month-old hearts from SNAP29-cKO mice for SNAP29. β-
actin was used as a loading control. 
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Figure 6. Telemetry electrocardiography analysis of adult SNAP29-cKO mice. (A) 
Representative telemetry ECG tracing from conscious 3-month-old SNAP29-cKO mice 
and littermate controls. Premature ventricular contractions (PVC) are marked by red 
arrows. (B) Representative surface and intracardiac ECG tracings from anesthetized 3-
month-old SNAP29-cKO mice and littermate controls undergoing ventricular ectopic 
stimulation. Prevalence of VT in stimulated 3-month-old SNAP29-cKO mice and 
littermate controls below.  
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Figure 7. Lipid droplet accumulation in SNAP29-cKO hearts. Oil red O staining of 
cryosections from 3-month-old SNAP29-cKO hearts. RV = right ventricle from solid 
boxed area; LV = left ventricle from dashed boxed area; upper scale bar = 1 mm; lower 
scale bar = 100 µm 
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Figure 8. Cardiac morphology, fibrosis, and function of SNAP29-cKO mice. (A) 
Wholemount images of representative 3-month-old SNAP29-cKO mouse heart with 
littermate control. (B) Heart weight to tibia length rations of SNAP29-cKO mouse hearts 
and littermate controls. (C) Masson’s trichrome stain of right (RV) and left (LV) ventricles 
of 3-month-old SNAP29-cKO mouse heart with littermate control. (D) Echocardiography 
analysis of 3-month-old and 8 month-old of SNAP29-cKO mouse hearts with littermate 
controls.   
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Figure 9. Expression levels of ICD proteins in SNAP29-cKO mouse hearts. Western 
blot analysis of desmosomal, gap junction, and FAJ proteins in 3-month-old SNAP29-
cKO hearts. GAPDH was used as a loading control.   
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Figure 10. Autophagy defects in SNAP29-cKO mouse hearts. (A) Western blot 
analysis of 3-month-old SNAP29-cKO mouse hearts for LC3B and p62. GAPDH was 
used as a loading control. (B) Immunofluorescence staining of 3-month-old hearts from 
SNAP29-cKO mice for LC3B (red), DSP (green), and JUP (white) and counterstained 
with DAPI (blue). Scale bar = 10 µm. At right, transmission electron micrographs of 
intercalated discs of 3-month-old SNAP29-cKO hearts. Multi-membrane structures in 
proximity to the ICD are marked by white arrow. Scale bar = 500 nm.   
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Figure 11. Autophagy markers are elevated in DSP-cKO mouse hearts. (A) Western 
blot analysis of 6-week-old hearts from DSP-cKO mice for LC3B and p62. GAPDH was 
used as a loading control. (B) Immunofluorescence staining of 6-week-old hearts from 
DSP-cKO mice for LC3B (red), DSP (green), and JUP (white) and counterstained with 
DAPI (blue). ICD localized LC3B marked by white arrows. Scale bar = 10 µm. 
Transmission electron micrographs at right of intercalated discs of 6-week-old DSP-cKO 
hearts. Multi-membrane structures are marked by black arrowheads. Scale bar = 500 
nm.   
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Figure 12. Disease-associated DSP mutations disrupt their interaction with 
SNAP29. (A) Diagram of DSP region (amino acids 500-1030) and mutations tested. (B) 
Diagram of SNAP29 region tested (full length). (C) Assay of β-galactosidase reporter 
activity in mated yeast expressing wildtype or mutant DSP-F2 and SNAP29 yeast-2-
hybrid constructs. Wildtype or mutant DSP-F2 mated with empty prey vector (pGADT7) 
are negative controls. * = p<0.05 
 
A B
SPEC t-SNARECoiled coil PLEC
`
-g
al
ac
to
si
da
se
 U
ni
ts
DSP-F2 Bait
SNAP29 Bait
Q616P H618P
WT
Interaction
Mutant DSP
Interactions
DS
P-
F2
 + 
SN
AP
29
DS
P-
F2
 Q
61
6P
 + 
SN
AP
29
DS
P-
F2
 H
61
8P
 + 
SN
AP
29
DS
P-
F2
 + 
pG
AD
T7
DS
P-
F2
 Q
61
6P
 + 
pG
AD
T7
DS
P-
F2
 H
61
8P
 + 
pG
AD
T7
90
80
70
60
50
40
20
30
10
0
100 aa 100 aa
C
*
      
 69 
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5.1 Characterization of Cardiomyocyte Function following loss of SNAP29 
5.1.1 Desmosomal and gap junction proteins are specifically reduced in SNAP29 KO 
CMs 
To determine the primary effects of knockout of SNAP29 in cardiomyocytes, 
desmosomal, gap junction, and FAJ protein levels were assessed in SNAP29flox/flox 
neonatal cardiomyocytes infected by Ad-Cre or Ad-LacZ as control. To control for 
starvation induced autophagy in culture, cardiomyocytes were serum- and glucose-
starved then returned to complete medium for 2 hours prior to collection. Western blot 
analysis revealed efficient loss of SNAP29 at 48 hours post infection (Fig. 13). All 
measured desmosomal and gap junction proteins were strikingly reduced with only 
minor effects on FAJ proteins in Ad-Cre infected neonatal cardiomyocytes compared to 
controls (Fig. 13), suggesting that SNAP29 has specific effects on the desmosome and 
gap junction in vitro. To determine the primary effects of knockout of SNAP29 on protein 
degradation in cardiomyocytes, western blot was performed in these cells for markers of 
autophagy. Western blot analysis revealed accumulation of the autophagosome marker 
LC3B and the UPS-autophagy crosstalk protein p62 (Fig. 13). These findings reveal that 
loss of SNAP29 in cardiomyocytes in vitro leads to molecular defects consistent with the 
SNAP29-cKO mouse, suggesting that these are primary consequences of loss of 
SNAP29. 
 
5.1.2 SNAP29 knockout CMs exhibit baseline arrhythmias 
To determine the functional effects of loss of SNAP29 in vitro, neonatal 
cardiomyocytes were grown in the xCELLigence® RTCA CardioECR system and 
monitored for electrical activity and contractility by measuring electrical field potentials 
and cell-induced impedence, respectively. Analysis of baseline electrical firing and 
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contractility rates revealed significantly increased variability as measured by coefficient 
of variance in SNAP29 deficient CMs (Fig. 14A/B). These effects were observed 
independent of any changes in average firing rate (Fig. 14C), suggesting that loss of 
SNAP29 has detrimental effects on cardiomyocyte electrophysiology independent of any 
histological changes in the heart. 
 
5.1.3 Autophagic flux is maintained in SNAP29 KO CMs 
Loss of cardiomyocyte SNAP29 appears to lead to accumulation of LC3 positive 
vesicles (Fig. 10B). This can be caused by either an increase in activation of autophagy 
(faster rate or autophagosome formation) or a reduction in autophagic flux (reduced rate 
of autophagosome clearance) (Klionsky, Abdelmohsen et al. 2016). To determine if loss 
of SNAP29 leads to reduced autophagic flux, SNAP29-deficient cardiomyocytes were 
infected with BacMam virus containing the autophagosome reporter LC3-GFP (green) 
and incubated with lysotracker (red) to stain lysosomes. In this system, autophagosomes 
are marked by LC3-GFP only and appear green while autophagosome that have fused 
with the lysosome, called autolysosomes, are both LC3-GFP and lysotracker positive 
and appear yellow. Analysis of SNAP29-deficient cardiomyocytes in this system reveal 
increased total levels of autophagic vacuoles (Fig. 15A/B). This occurred without effects 
on autophagic flux, as measured by the ratio between autophagosomes and lysosomes 
(Fig.15D). Altogether this suggests that autophagy is upregulated in SNAP29-deficient 
cardiomyocytes and that autophagic flux is not blocked. 
 
5.1.4 Autophagy inhibition is sufficient to reverse desmosomal protein loss in SNAP29 
KO CMs 
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To assess the requirement for autophagy for the desmosomal and gap junction 
protein loss in SNAP29 deficient CMs, infected CMs were treated for with the lysosomal 
inhibitor, chloroquine (CQ), which effectively blocks degradation of proteins through 
autophagy (Klionsky, Abdelmohsen et al. 2016). Analysis of cardiomyocytes revealed 
restoration of DSP levels in SNAP29 deficient CMs after treatment with CQ (Fig. 16), 
suggesting that DSP loss in this model is autophagy dependent.  
 
Chapters 3-6, in part are currently being prepared for submission for publication 
of the material. Pellman, Jason; Lyon, Robert; Liang, Yan; Mezzano, Valeria; Zanella, 
Fabian; Zhang, Jing; Nigam, Vishal; Gu, Yusu; Dalton, Nancy; Peterson, Kirk L.; Sheikh, 
Farah. The dissertation author was the primary investigator and author of this material. 
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Figure 13. Altered expression of ICD and autophagy proteins in SNAP29-deficient 
neonatal mouse cardiomyocytes. Western blot analysis of Ad-Cre or Ad-LacZ control 
infected SNAP29-floxed neonatal mouse cardiomyocytes. Cells were infected 24 hours 
after plating and collected 48 hours after infection. GAPDH was used as a loading 
control. 
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Figure 14. Electrophysiological function in SNAP29-deficient neonatal mouse 
cardiomyocytes. (A) Representative contraction and electrical potential tracings from 
Ad-Cre or Ad-LacZ control infected SNAP29-floxed neonatal mouse cardiomyocytes. (B) 
Analysis of beating rate variability via coefficient of variability in SNAP29-deficient 
neonatal mouse cardiomyocytes and controls. * = p < 0.05 (C) Average beating rates in 
Ad-Cre or Ad-LacZ control infected SNAP29-floxed neonatal mouse cardiomyocytes 
(mean ± SEM). NS = not significant. 
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Figure 15. Elevated autophagy in SNAP29-deficient neonatal mouse 
cardiomyocytes. (A) Representative merged fluorescence microscopy images of Ad-
Cre or Ad-LacZ control infected SNAP29-floxed neonatal mouse cardiomyocytes 
expressing GFP-LC3 (green) and stained with Lysotracker (red). Scale bar = 10 µm. (B) 
Analysis of total number of green (GFP-LC3 positive autophagosomes) and yellow 
(GFP-LC3 and Lysotracker positive autolysosomes) puncta per cell. (C) Average 
number of autophagosomes and lysosomes per cell. (D) Ratio of autophagosomes and 
lysosomes per cell. N = 22 cells. * = p<0.05. NS = not significant.   
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Figure 16. Effects of autophagy inhibition on ICD protein expression in SNAP29-
deficient neonatal mouse cardiomyocytes. Western blot analysis of Ad-Cre or Ad-
LacZ control infected SNAP29-floxed neonatal mouse cardiomyocytes treated with 
chloroquine (CQ) or vehicle control. GAPDH is used as loading control. 
 
  
SNAP29
DSP
`-Actin
LacZ
Veh VehCQ CQ
Cre
      
 77 
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6.1 Cardiac Characterization of Global Loss of SNAP29 in vivo  
6.1.1 SNAP29 expression is lost in SNAP29 global knockout (SNAP29-gKO) hearts 
Global loss of SNAP29 has recently been shown to model features of the human 
neurocutaneous disease CEDNIK which stands for CErebral Dysgenesis, Neuropathy, 
Ichthyosis, and Keratoderma (Schiller, Seebode et al. 2016). This syndrome shares skin 
defects with the DSP mutation-based disease, Carvajal disease (Carvajal-Huerta 1998). 
Patients with CEDNIK are prone to sudden death during childhood, though the cause is 
poorly understood (Sprecher, Ishida-Yamamoto et al. 2005, Fuchs-Telem, Stewart et al. 
2011). Sudden cardiac death is also a common feature of ARVC (Thiene, Corrado et al. 
2007, Sen-Chowdhry, Morgan et al. 2010), therefore the global SNAP29 knockout 
mouse model was used to investigate the role of the heart in CEDNIK. The construct 
used for global knockout of SNAP29 (SNAP29-gKO) (Fig. 17A) ablates SNAP29 as 
evidenced by analysis of multiple organs for SNAP29 protein expression (Fig. 17B). This 
model was utilized to determine if CEDNIK syndrome exhibits underlying cardiac 
defects. 
 
6.1.2 SNAP29-gKO mice exhibit perinatal lethality, growth retardation, and skin peeling 
SNAP29-gKO mice are born but die after birth between postnatal day 0 (P0) and 
P5 (Fig. 18A). SNAP29-gKO mouse pups are born at similar weight to littermate controls 
but surviving pups are significantly smaller by P3 (P3) (Fig. 18B). Gross analysis of pups 
reveals skin peeling defects in SNAP29-gKO mice and not in littermate controls (Fig. 
18B). These findings suggest that SNAP29 is essential for postnatal survival in the 
mouse. 
 
6.1.3 SNAP29-gKO mouse hearts have normal morphology 
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To determine whether loss of SNAP29 affects heart morphology, embryonic and 
neonatal SNAP29-gKO hearts were collected at E18.5, P0 and P3. Analysis of gross 
morphology and normalized heart weight revealed no differences between SNAP28-gKO 
hearts and wildtype controls (Fig. 18C), suggesting that SNAP29 does not have a role in 
cardiac morphology development. 
 
6.1.4 Cardiomyocytes from SNAP29-gKO mouse hearts exhibit arrhythmias in vitro 
To determine the functional effects of global loss of SNAP29, neonatal SNAP29-
gKO and littermate control cardiomyocytes were grown in the xCELLigence® RTCA 
CardioECR system and monitored for electrical activity and contractility by measuring 
electrical field potentials and cell-induced impedence, respectively. Analysis of baseline 
electrical firing and contractility rates revealed significantly increased variability as 
measured by coefficient of variance in SNAP29-gKO CMs (Fig. 19A/B). These effects 
were observed independent of any changes in average firing rate (Fig. 19C). These 
findings suggest that global loss of SNAP29 has early detrimental effects on 
cardiomyocyte electrophysiology. 
 
6.1.5 Desmosomal proteins are specifically reduced in SNAP29-gKO hearts 
To assess the effects of global loss of SNAP29 on ICD protein levels, embryonic 
SNAP29-gKO hearts were analyzed for desmosomal, gap junction, and FAJ protein 
levels. Western blot analysis revealed specific loss of desmosomal and gap junction 
protein levels with no effect on FAJ proteins (Fig. 20) suggesting that SNAP29 loss leads 
to specific effects on the desmosome and gap junction in the heart. These findings 
mirror the effects of cardiac specific knockout of SNAP29 (Fig. 9) in the adult heart. 
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6.1.6 Markers of autophagy accumulate in SNAP29-gKO hearts 
To assess the effects of global loss of SNAP29 on autophagy, neonatal SNAP29-
gKO hearts were analyzed. Western blot analysis revealed a significant increase in 
LC3B levels (Fig. 21A), suggesting that autophagosomes were accumulating. 
Immunofluorescence analysis further revealed that LC3B was localized to the ICD (Fig. 
21B). TEM analysis revealed multi-membrane ultrastructural defects similar to 
autophagosomes and autolysosomes at the ICD (Fig. 21B), suggesting that the elevated 
LC3B is due to ICD-specific autophagosome accumulation. These findings mirror the 
results from SNAP29-cKO (Fig. 10) and DSP-cKO (Fig. 11) adult hearts, suggesting that 
autophagosomes and autolysosomes are consistently accumulated after loss of 
SNAP29. 
 
Chapters 3-6, in part are currently being prepared for submission for publication 
of the material. Pellman, Jason; Lyon, Robert; Liang, Yan; Mezzano, Valeria; Zanella, 
Fabian; Zhang, Jing; Nigam, Vishal; Gu, Yusu; Dalton, Nancy; Peterson, Kirk L.; Sheikh, 
Farah. The dissertation author was the primary investigator and author of this material. 
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Figure 17. SNAP29 is ablated in global SNAP29 knockout (SNAP29-gKO) neonatal 
mice. (A) Genetic construct used to globally knockout SNAP29 in mouse. (B) Western 
blot analysis of organs from SNAP29-gKO P1 mice. β-actin is used as a loading control. 
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Figure 18. SNAP29-gKO mice exhibit perinatal lethality, growth retardation, and 
skin peeling without changes in cardiac morphology. (A) Kaplan-Meier survival 
curve of SNAP29-gKO mice. (B) Gross morphology of SNAP29-gKO pups at P2. (C) 
Gross morphology of SNAP29-gKO hearts at P0. (D) Heart weight to tibia length ratios 
of SNAP29-gKO hearts at P0. 
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Figure 19. Electrophysiological function in SNAP29-gKO cardiomyocytes. (A) 
Representative contraction and electrical potential tracings from SNAP29-gKO and 
littermate control neonatal mouse cardiomyocytes. (B) Analysis of beating rate variability 
via coefficient of variability in SNAP29-gKO and littermate control neonatal mouse 
cardiomyocytes. (C) Average beating rates in SNAP29-gKO and littermate control 
neonatal mouse cardiomyocytes neonatal mouse cardiomyocytes (mean ± SEM). 
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Figure 20. Expression levels of ICD proteins in SNAP29-gKO mouse hearts. 
Western blot analysis of desmosomal, gap junction, and FAJ proteins in P3 or E18.5 
SNAP29-gKO hearts. β-tubulin and GAPDH were used as a loading control.   
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Figure 21. Autophagy defects in SNAP29-gKO mouse hearts. (A) Western blot 
analysis of P2 SNAP29-gKO mouse hearts for LC3B and p62. GAPDH was used as a 
loading control. (B) Immunofluorescence staining of P2 hearts from SNAP29-gKO mice 
for LC3B (red), DSP (green), and JUP (white) and counterstained with DAPI (blue). 
Scale bar = 10 µm. At right, transmission electron micrographs of intercalated discs of 
P2 SNAP29-gKO hearts. Multi-membrane structures are marked by black arrowheads. 
Scale bar = 500 nm.  
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7.1 SNAP29 is a novel desmosomal interacting protein 
The desmosome is classically thought to primarily have a structural function in 
the cell, however more recently non-structural roles of desmosomal proteins have begun 
to be described. This dissertation provides evidence for the SNARE protein SNAP29 as 
a novel cardiac desmosomal protein through its newly identified interaction with the N-
terminus of DSP. The function of SNAP29 in the heart has not been investigated; 
however, previous studies have proposed a role for SNAP29 in protein degradation via 
autophagy (Itakura, Kishi-Itakura et al. 2012, Morelli, Ginefra et al. 2014). SNAP29 is a 
29 kDa SNARE protein of the SNAP25 family, which are generally though to mediate 
membrane fusion processes as part of a complex with syntaxin and VAMP family 
SNAREs (Wong, Xu et al. 1999, Su, Mochida et al. 2001). The studies in this 
dissertation provide evidence for a novel protein that directly links the desmosome to 
protein degradation mechanisms, which is required for homeostatic cardiac rhythm and 
lipid control. 
 
7.2 SNAP29 is a negative regulator of autophagy 
In vitro studies in SNAP29 deficient neonatal cardiomyocytes demonstrate that 
SNAP29 may act to limit autophagosome production in cardiomyocytes, based on the 
observations of (i) increased number of LC3 puncta (autophagosomes and 
autolysosomes) in SNAP29 deficient versus control cardiomyocytes and (ii) similar ratios 
of autophagosome to autolyosomes (no change in autophagic flux) in SNAP29 deficient 
versus control cardiomyocytes. These findings suggested that cardiomyocyte SNAP29 
functions as a negative regulator of autophagy and is not required for autophagosome-
lysosome fusion. These findings are in contrast to previous studies in the field that 
suggested a role for SNAP29 as a positive regulator of autophagy and a blocker of 
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autophagosome-lysosome fusion (Itakura, Kishi-Itakura et al. 2012, Morelli, Ginefra et al. 
2014). Specifically, siRNA knockdown of SNAP29 in HeLa cells and Drosophila lead to 
an increase in LC3 positive puncta; however, in these systems loss of SNAP29 also 
caused an increase in the ratio of autophagosomes to autolyosomes, and thus, blockade 
of autophagic flux suggestive of its requirement in autophagosome-lysosome fusion 
(Itakura, Kishi-Itakura et al. 2012, Morelli, Ginefra et al. 2014). It is possible that SNAP29 
may have different effects on autophagy according to cell type, as autophagy signaling is 
different across cell lines (Klionsky, Abdelmohsen et al. 2016). Furthermore, a study 
comparing autophagic response in cardiomyocytes and skin fibroblasts revealed 
strikingly different responses to autophagic stress (Hashem, Perry et al. 2015). 
Interestingly, SNAP29 localization is found in the cytoplasm in cell lines and Drosophila; 
however, in cardiomyocytes SNAP29 presents at a unique localization associated with 
ICD, thus its differential compartmentalized expression pattern and thus, targets, may 
result in distinct protein degradation functions in different cell types. 
 
7.3 Desmosomal proteins are targeted by SNAP29-mediated autophagy 
In vitro and in vivo studies in SNAP29 deficient cardiomyocytes demonstrate that 
SNAP29 deficiency specifically targets desmosomal protein loss/degradation via 
autophagy-mediated mechanisms. In vivo studies in SNAP29 deficient hearts suggest 
that SNAP29 may impact a hierarchy of proteins associated with ICD, as specific loss of 
DSP, PKP2 and Cx43 protein levels were observed. In vitro studies in SNAP29 deficient 
cardiomyocytes also confirm that ICD defects are primary to SNAP29 loss. Data from 
our previous mouse models of DSP deficiency supports the theme of hierarchical 
organization of ICD proteins. DSP deficient mouse hearts similarly exhibit specific loss of 
desmosomal and gap junction proteins without affecting FAJ proteins (Lyon, Mezzano et 
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al. 2014). In vitro studies in DSP deficient cardiomyocytes have also demonstrated that 
these effects are primary to loss of DSP and independent of cardiac structural defects 
(Lyon, Mezzano et al. 2014), suggesting that desmosome and gap junction regulation is 
directly linked. The effects on a subset of desmosomal proteins in SNAP29 deficient 
hearts suggest that complex organization within the desmosome itself may also be 
hierarchical. Previous studies on mouse models deficient in other desmosomal proteins 
have also shown varying effects on other desmosomal protein. For example our DSP 
deficient mouse model exhibits loss of DSP, PKP2, DSC2, and DSG2 with no change in 
JUP (Lyon, Mezzano et al. 2014). Meanwhile, in hearts from DSG2 cardiac specific 
knockout mice, neither DSP nor JUP are reduced, though other desmosomal proteins 
were not analyzed (Kant, Holthofer et al. 2015). In mice expressing mutant iASSP, a 
recently identified ICD protein and DSP interactor, DSP levels are unaffected, though 
localization at the ICD is reduced (Notari, Hu et al. 2015). All together these studies 
suggest that the desmosome is regulated such that primary loss of a protein from the 
desmosome may have effects only its most closely associated interactors, e.g. loss of 
SNAP29 leads to loss of DSP, while leaving the rest of the complex relatively unaffected.  
In vitro studies in SNAP29 deficient cardiomyocytes suggest that DSP is targeted 
by autophagy as a result of loss of SNAP29. Autophagy inhibition in SNAP29 deficient 
cardiomyocytes in vitro with the lysosomal inhibitor chloroquine was sufficient to restore 
DSP protein levels. The role of autophagy is corroborated by in vivo ultrastructural data 
revealing accumulation of autophagosome-like and autolysosome-like structures 
specifically at the ICD of SNAP29 deficient mouse hearts. The autophagosome marker 
LC3 also appears specifically at the ICD in these hearts, suggesting that autophagy is 
active at the ICD. These findings are in line with previous studies suggesting that the 
ICD may an active site of autophagy (Hilenski, Terracio et al. 1992, Nepomnyashchikh, 
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Lushnikova et al. 2000, Lange, Xiang et al. 2005, Balasubramanian, Mani et al. 2006, 
Hirschy, Croquelois et al. 2010). These studies altogether establish that DSP can be 
targeted and degraded by autophagy protein degradation mechanisms in cardiomyoctes. 
 
7.4 SNAP29-mediated autophagy protects cardiomyocytes from arrhythmias 
In vivo studies utilizing cardiac specific SNAP29 knockout mice (SNAP29-cKO) 
demonstrates a role for SNAP29 loss in predisposing mice to premature and inducible 
ventricular arrhythmias. Premature and inducible ventricular arrhythmias have also been 
observed in DSP-cKO mice and PKP2 heterozygous knockout mice (Cerrone, Noorman 
et al. 2012, Lyon, Mezzano et al. 2014), supporting these data support shared functional 
consequences associated with loss of these protein interactions. In PKP2 global 
heterozygous knockout mice, ventricular arrhythmias are the primary disease feature 
observed (Cerrone, Noorman et al. 2012). This parallels features of SNAP29-cKO mice 
which exhibit reduced PKP2 in the context of ventricular arrhythmias. In DSP-cKO mice 
which have now been shown to express reduced levels of SNAP29 at the ICD, 
premature ventricular contractions and inducible ventricular arrhythmias are both 
electrical defects in this model (Lyon, Mezzano et al. 2014). Previous studies in DSP-
cKO mice and DSP deficient cardiomyocytes suggest that Cx43 loss may trigger the 
cardiac arrhythmias underlying ARVC. Our studies also show that Cx43 levels are 
reduced with loss of SNAP29 and that this is associated with arrhythmias in vivo and in 
vitro, suggesting that loss of Cx43 may be a common underlying mechanism in 
development of these ventricular arrhythmias. This supported by findings in Cx43 
cardiac specific knockout models that show ventricular arrhythmias as the major disease 
feature in these mice (Jansen, Noorman et al. 2012). Furthermore, both SNAP29-cKO 
and DSP-cKO models exhibit consistent loss of DSP, Cx43 and SNAP29 underlying 
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ventricular arrhythmias which reveal the possibility that SNAP29 may mediate the 
previously observed functional interaction between DSP and Cx43. Both of these mouse 
models also feature elevated autophagy levels. Previous studies on Cx43 turnover in 
vitro support a role for autophagy in Cx43 degradation in cardiomyocytes (Su and Lau 
2012, Basheer, Harris et al. 2015), suggesting that changes in SNAP29-mediated 
autophagy may alter Cx43 levels.  
 
7.5 SNAP29-mediated autophagy is required for cardiomyocyte lipid droplet 
homeostasis 
In vivo studies on SNAP29 deficient hearts suggest a role for SNAP29 in lipid 
droplet homeostasis as evidenced by accumulation of lipid droplets in cardiomyocytes of 
the right ventricles of these hearts. Lipid defects are also present in DSP-cKO hearts as 
observed by fatty deposition (Lyon, Mezzano et al. 2014). Lipid droplets have also been 
reported in ultrastructural studies on hearts for ARVC patients, who harbor underlying 
desmosomal defects (Masani, Aizawa et al. 1990, Basso, Czarnowska et al. 2006). 
Similarly, human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) 
from ARVC patients with PKP2 mutations also accumulate lipid droplets (Kim, Wong et 
al. 2013, Ma, Wei et al. 2013), suggesting that this may be a common underlying feature 
of desmosomal disease. The selective accumulation of lipid droplets in the right ventricle 
of SNAP29 deficient hearts may arise from right vs. left metabolic differences in the 
heart. Cardiomyocytes from the right heart have been shown to be sufficient for 
development of fatty accumulation in mice specifically lacking DSP in the second heart 
field which developmentally forms the right heart (Lombardi, Dong et al. 2009). Studies 
in hiPSC-CMs from ARVC patients with PKP2 mutations have previously identified 
activation of peroxisome proliferator-activated receptor gamma (PPARγ), a 
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proadipogenic transcription factor (Ma, Wei et al. 2013). Interestingly, analysis of cardiac 
biopsies from ARVC patients have revealed increased levels of PPARγ in RV compared 
to LV tissue, suggesting that differences in adipogenic signaling may underlie the 
increased propensity for RV lipid accumulation. 
Lipid droplet homeostasis has previously been shown to be regulated by 
autophagy mechanisms . LC3 has been observed on starvation induced lipid droplets in 
the mouse heart (Shibata, Yoshimura et al. 2009). Additional studies in cell lines have 
revealed that knockdown of LC3 leads to reduced lipid droplet numbers (Shibata, 
Yoshimura et al. 2010), suggesting that autophagy may be required for lipid droplet 
production. The role of SNAP29 in autophagy suggest that these mechanisms may be at 
play in SNAP29 deficient hearts. While there is no previously described relationship 
between SNAP29 and lipid droplet homeostasis, another SNAP25 protein family 
member has been shown in vitro to regulate lipid droplet size in 3T3 cells and also 
localize to lipid droplets in HL-1 cells (Bostrom, Andersson et al. 2007). It remains to be 
determined if SNAP29 has direct effects on lipid droplet formation or turnover in the 
heart. 
 
7.6 SNAP29-mediated autophagy defects may underlie a subset of early ARVC 
disease features 
Previous studies using mouse models and human biopsies have proposed 
various pathways underlying ARVC including Wnt/b-catenin signaling and the Hippo 
pathway (Garcia-Gras, Lombardi et al. 2006, Chen, Gurha et al. 2014). For the first time 
through this dissertation, our data demonstrates that loss of SNAP29 expression, 
localization and functions associated with autophagy are defective in a mouse model of 
ARVC as evidenced by the loss of SNAP29 from the ICD and accumulation of 
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autophagosome-like and autolysosome-like vesicles at the ICD in DSP deficient mouse 
hearts. The loss of SNAP29 is also been demonstrated in hiPSC-CMs derived from 
ARVC patients, suggesting that loss of SNAP29 may also be a feature of human ARVC. 
As shown in SNAP29 deficient mouse hearts, these molecular and ultrastructural 
features are associated with ventricular arrhythmias and lipid accumulation. This 
suggests that loss of SNAP29 and SNAP29-mediated autophagy mechanisms may 
contribute to development of a subset of disease features ARVC. Some evidence of 
vesicular defects at the ICD has been observed in DSG2 deficient mouse hearts as well 
as in ARVC patient biopsies (Basso, Czarnowska et al. 2006, Kant, Krull et al. 2012), 
therefore autophagic defects may represent an underappreciated feature underlying 
ARVC. These mechanisms may be especially relevant during the “concealed” phase of 
ARVC, during which electrical disease features are the only cardiac defects (Dalal, Nasir 
et al. 2005, Basso, Czarnowska et al. 2006). SNAP29 deficient hearts exhibit 
predominantly electrical disease features; therefore SNAP29-mediated autophagy 
defects may be particularly important for development of these features of ARVC. 
Analysis of electrical forms of ARVC may reveal whether these molecular and 
ultrastructural defects are present and contribute to this specific disease feature 
development. 
 
7.7 Cardiac desmosomal and autophagy defects underlie a SNAP29-deficient mouse 
model of CEDNIK syndrome 
In vivo and in vitro studies in SNAP29 deficient heart and cardiomyocytes 
suggest a potential role for SNAP29 at the desmosome in other human diseases. 
SNAP29 mutations in humans are associated with the neurocutaneous syndrome called 
CEDNIK syndrome (cerebral dysgenesis, neuropathy, ichthyosis, and keratoderma) that 
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ultimately results in sudden death of pediatric patients between 6-11 years of age, 
though the hearts of these patients have not been examined in detail (Sprecher, Ishida-
Yamamoto et al. 2005, Fuchs-Telem, Stewart et al. 2011). Global loss of SNAP29 in 
mouse has previously been shown to lead to skin defects and early lethality at postnatal 
day one (Schiller, Seebode et al. 2016). Skin specific knockout of SNAP29 in mouse 
also leads to the same skin defects and lethality (Schiller, Seebode et al. 2016), 
suggesting that cause of death in mice originates from the skin. However, human 
patients live for years before death and do not appear to die of skin-related causes 
(Sprecher, Ishida-Yamamoto et al. 2005, Fuchs-Telem, Stewart et al. 2011), therefore 
there may be previously unappreciated disease features underlying CEDNIK.  
Analysis of hearts from SNAP29-gKO mice which model CEDNIK have revealed 
striking early cardiac desmosomal and gap junction defects by E18.5. In vitro studies in 
cardiomyocytes reveal electrical defects in the form of cardiomyocyte arrhythmias. 
These findings recapitulate features from cardiomyocyte specific SNAP29 deficient 
models and early electrical disease features of ARVC. ARVC has more recently been 
observed in pediatric populations ranging from infants to children in their teens, though 
diagnosis is more difficult (Daliento, Turrini et al. 1995, Nishikawa, Ishiyama et al. 1999, 
Garcia-Gras, Lombardi et al. 2006, Rey, Rodriguez-Nunez et al. 2007, Wong, 
AbdurRazak et al. 2008). Altogether, this suggests the possibility that cardiac defects 
may underlie CEDNIK syndrome and may contribute to sudden death in CEDNIK 
patients. 
SNAP29 mediated desmosomal targeted autophagy defects could also 
potentially underlie the brain defects in CEDNIK syndrome. Both neurons and 
cardiomyocytes rely on cell-cell communication to drive the electrical activity. A major 
feature of the cardiomyocytes from SNAP29-gKO mice is arrhythmia with underlying loss 
95 
 
  
of Cx43. It is interesting to note that electrical defects are also present in CEDNIK 
patients in the nervous system, observed as neuropathy (Sprecher, Ishida-Yamamoto et 
al. 2005, Fuchs-Telem, Stewart et al. 2011). A role for Cx43 in neurons has been 
investigated in a model of glaucoma induced neuropathy, wherein Cx43 loss appears to 
contribute to development of neuropathy features (Malone, Miao et al. 2007). These 
studies altogether suggest that SNAP29-mediated loss of Cx43 may potentially 
contribute to nervous system defects in CEDNIK. Furthermore, the role of the 
desmosome of the brain is unclear. There is some evidence of desmosomes in the 
nervous system. For example the desmosomal protein DSG1 has been observed in the 
brain, specifically in the corpus callosum, though other desmosomal proteins have not 
been examined (Miyata, Yoshikawa et al. 2015). Interestingly, this region of the brain is 
also dysmorphic in CEDNIK patients (Sprecher, Ishida-Yamamoto et al. 2005, Fuchs-
Telem, Stewart et al. 2011), opening up the possibility of desmosomal-related 
mechanisms in disease pathogenesis in the brain. 
Desmosomal targeted autophagy defects may also underlie the skin defects in 
CEDNIK syndrome as CEDNIK patients and mice exhibiting SNAP29 loss also display 
similar skin defects as patients with Carvajal syndrome, which is associated with 
recessive DSP loss (Carvajal-Huerta 1998, Norgett, Hatsell et al. 2000). It has also been 
reported that markers of autophagy are increased in skin from SNAP29 global knockout 
mice (Schiller, Seebode et al. 2016). Based on the connection between SNAP29-
mediated autophagy and desmosomal protein loss as well as the presence of 
desmosomal proteins in the affected organs, CEDNIK may be a disease of the 
desmosome. Furthermore, yeast-2-hybrid studies on DSP mutations associated with the 
heart and skin disease erythrokeratodermia-cardiomyopathy syndrome (Boyden, Kam et 
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al. 2016) revealed a loss of interaction with SNAP29, suggesting that disruption of the 
DSP-SNAP29 interaction may underlie diseases of both the heart and skin. 
 
 
7.8 Conclusions 
In conclusion, SNAP29 is a novel desmosomal protein whose function in 
autophagy is required for maintenance of desmosomal and gap junction protein levels in 
the heart. SNAP29 appears to maintain DSP levels in cardiomyocytes through its role as 
a negative regulator of autophagy in cardiomyocytes. Loss of SNAP29 in the heart 
triggers a reduction in desmosomal and gap junction proteins and accumulation of 
autophagy markers leading to lipid accumulation and ventricular arrhythmias 
characteristic of ARVC. Loss of SNAP29 levels, localization and function are also 
observed in a DSP-deficient mouse model of ARVC and loss of SNAP29 levels are 
observed in hiPSC-CMs from ARVC patents, suggesting that disrupted autophagy 
function may be a molecular feature of ARVC. In a mouse model of CEDNIK syndrome, 
cardiac desmosomal defects are present in the context of cardiomyocyte electrical and 
autophagy defects reminiscent of SNAP29-deficient and DSP-deficient hearts. 
Altogether, these findings suggest that SNAP29 protects desmosomes from targeted 
protein degradation to restrict cardiac arrhythmias. 
 
7.9 Future Studies 
 These studies have identified a role for SNAP29 in autophagy. SNAP29 appears 
to be a negative regulator of autophagy based on the increase in autophagic vesicles 
without a change in flux in the absence of SNAP29. To more precisely determine how 
SNAP29 exerts control on autophagy, additional biochemical studies are required. 
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Based on the potential role of SNAP29 as an inhibitor of SNARE complex disassembly, 
examination of mechanisms at various steps of autophagy, especially at the termination 
of autophagy, may reveal whether complex disassembly is affected. Based on the 
maintenance of autophagic flux in SNAP29-deficient cardiomyocytes, it is unlikely that 
SNAP29 is required for autophagosome-lysosome fusion. SNAP29 has previously been 
described as a promiscuous SNARE due to proposed interactions with numerous 
SNARE complexes (Hohenstein and Roche 2001), however none of these have been 
examined in the heart. The localization of SNAP29 at the desmosome in cardiomyocytes 
and the appearance of autophagosomes at the ICD under disease conditions suggest 
that it may participate locally in autophagy at the ICD. Interestingly, VAMP5 has 
previously identified at the ICD (Takahashi, Tajika et al. 2013), however it has not been 
determined whether it can complex with SNAP29. A previously proposed SNAP29 
interacting protein Rab24 (Schardt, Brinkmann et al. 2009) is thought to be required for 
the final steps in autophagy that are responsible for clearance of autolysosomes (Yla-
Anttila, Mikkonen et al. 2015), therefore it is possible that autophagy clearance 
mechanisms are also affected in a SNAP29-deficient setting. Identification and 
characterization of a cardiomyocyte SNAP29-containing SNARE complex may shed light 
on the unique protein degradation mechanisms at play at the ICD. 
These studies have identified a potential role for autophagy in ARVC. Loss of 
desmosomal proteins is a common molecular hallmark of ARVC, though the 
mechanisms responsible are not established. Disruption of autophagy underlies our 
DSP-deficient mouse model of ARVC, however the extent to which it is responsible for 
development of disease features has yet to be determined. Recent studies have 
implicated protein degradation mechanisms in ischemia induced loss of Cx43 (Martins-
Marques, Catarino et al. 2015), a key protein thought to be involved in the ventricular 
98 
 
  
arrhythmias in ARVC (Lyon, Mezzano et al. 2014), however the these mechanisms have 
not been assessed in the context of ARVC. Future studies that take advantage of the 
DSP-cKO mouse line would be able to test the effects of pharmacological or genetic 
inhibition of autophagy in the mouse in vivo by treating mice with autophagy inhibitors (3-
MA or chloroquine) or crossing the line with the autophagy deficient beclin-1 
heterozygous knockout mouse. This can also be addressed in vitro by similarly inhibiting 
autophagy in DSP-deficient cardiomyocytes. These studies would have the potential to 
provide insight on whether there are therapeutic benefits to targeting protein degradation 
pathways in ARVC. 
 Cardiac desmosomal turnover mechanisms remain poorly understood, though 
they have the potential to impact cardiac function and disease. These studies have 
identified a link between DSP degradation and SNAP29 mediated degradation via 
autophagy. However, the mechanisms responsible for the targeting of DSP and other 
ICD proteins for degradation in the absence of SNAP29 remain unclear. Studies utilizing 
the SNAP29-cKO and DSP-cKO mouse lines could identify the protein complexes 
involved in loading of desmosomal protein into the autophagosome. Both of these 
models feature accumulation of autophagosomes at the ICD, making them ideal systems 
to detect the molecular complexes associating with them. 
 Mutation analysis of DSP has revealed the existence of DSP mutants associated 
with an array of heart and skin disease features (Boyden, Kam et al. 2016), however it 
remains unclear what regulatory mechanisms are shared between the two organs. 
Based on the studies in this dissertation, SNAP29 may be a downstream regulator of 
desmosome function that can impact both heart and skin. The interaction between 
SNAP29 and the desmosome may be disrupted by disease associated mutation and 
lead to defects in the heart and skin. Interaction analysis between SNAP29 and 
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desmosomal mutations may reveal the importance of this interaction in development of 
desmosome-based disease. Protein interaction studies focused on these mutations may 
reveal disrupted interactions with SNAP29 that could contribute to development of 
disease. 
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